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BIOMIMETIC MACROMOLECULES FOR MACROPHAGE 
TARGETING AND MODULATION 
 
JOSHUA WHITED 
 
ABSTRACT 
Carbohydrate recognition has come to the forefront of biological aiming to uncover the 
mechanisms of physiological and pathological processes. Cell surface glycans are involved 
in processes including cellular adhesion, cell signaling, and immune response. A new 
approach for profiling cell surface glycans has great potential for a wide range of 
biomedical applications. Lectins have been conventionally used to determine the structure 
and function of glycoproteins, however, their numbers are still restricted compared to the 
number of glycan structures. Boronic acid has proven a remarkable small molecule capable 
of binding diols in aqueous solution. This interaction indicates boronic acid derived 
molecules may serve as lectin mimetics for profiling and targeting cell surface glycans. In 
the first part of this dissertation study the specific binding site of boronic acid to individual 
pyranosides was confirmed followed by the synthesis and evaluation of protein-boronic 
acid conjugates as lectin mimetics.  
3-aminophenylboronic acid was conjugated to gluco-, manno- and galactopyranosides, 
followed by methylation, both under basic conditions.  Based on a specific permethylation 
product for the carbohydrate, boronic acid specificity towards 1,2 and 1,3 diol 
configurations was confirmed by 1H, 13C NMR, and mass spectrometry. As a result, unique 
binding profiles were observed for each pyranoside. Next, bovine serum albumin (BSA)-
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PBA conjugates were synthesized in a density controlled affording multivalent lectin 
mimetics. The resultant BSA-PBA conjugates were characterized by SDS-PAGE and 
MALDI-TOF MS. Cell surface glycan binding capacity was confirmed by a competitive 
lectin assay examined by flow cytometry. 
Macrophages (Mϕ) express lectins as receptors for specific immune responses. 
Synthetic glycans are candidates for targeting cell surface lectins and for 
immunomodulation applications. In the second part of this dissertation, novel N-glycan 
polymers were synthesized and their immunomodulation effects were examined. N-linked 
glycopolymers were synthesized via cyanoxyl-mediated free radical polymerization 
(CMFRP). Then, their cytotoxicity and cell activation abilities against RAW 264.7 cells 
were examined. As a result, N-glycan polymers showed no cytotoxicity at a concentration 
of 1,250 mg/mL except the N-α2,6-sialolactosyl polymer, which proved cytotoxic at 1250 
µg/mL. N-α2,3-sialolactosyl polymer showed the strongest activity for inducing cell 
surface marker expression compared to controls, indicating high Mϕ modulation activity. 
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CHAPTER I 
INTRODUCTION 
1.1 Glycans, glycosylation and glycomics 
Following the completion of the Human Genome Project in 2003, research entered a 
new post genomics era. Down from first predictions of over 100,000 protein encoding 
genes to now 20,000-25,000 it has become clear that the number of proteins in a cell is 
significantly higher than predicated solely by gene code translation to messenger 
ribonucleic acid (mRNA).1-3 The diversity of expressed proteins is controlled by varying 
types of mRNA produced from individual genes. These proteins perform a vast array of 
functions, many of which are facilitated through co- and post-translational modifications 
(PTM) before acquiring full or sometimes multiple functionalities.4-6 Glycosylation, 
perhaps the most complicated and varied type of PTM, is the attachment of oligosaccharide 
moieties to the protein.7-9 The complex character and varying attachments of each 
glycoform are substantial enough to dictate protein function and property.10-13 
Heterogeneity of glycans arises from the non-template driven nature of glycan 
biosynthesis, lack of proof reading machinery, and a large number of tissue specific 
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transferases and enzymatic glycosidases. Collectively, these justify the exponential number 
of patterns seen because of differing composition and branching. The affect is ambiguous, 
adding to both cellular individuality and function, while at the same time making glycomics 
a challenging area because of its complexity in comparison to both protein and nucleic 
acids.14-16 Thus there is an urgent to need to detect, identify, and characterize glycans in a 
rapid manner. 
1.1.1 Glycan structure 
There are 10 monosaccharides used by mammals in enzymatic glycosylation processes. 
These are glucose (Glc), galactose (Gal), mannose (Man), sialic acid (SA), N-
acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), fucose (Fuc), xylose 
(Xyl), glucuronic acid (GlcA), and iduronic acid (Figure 1).17 The Golgi complex in 
eukaryotic cells is of particular importance, in processing both glycoproteins and 
glycolipids, because it contains a set of glycosylation enzymes responsible for elongation 
and branching of saccharide chains.18,19 Different types of glycoproteins contain a shared 
pattern of glycosylation that can be divided into three major categories. O-linked glycans 
are typically linked to either Serine (Ser) or Threonine (Thr) residues, N-linked glycans 
linked to Asparagine residues and finally glycosaminoglycans that are also Ser or Thr 
anchored but remain linear instead of branched.20,21 Lipid glycosylation involves 
gangliosides which are composed of a glycosphingolipid with one or more SAs 
attached.22,23 Equally important are cytoplasmic glycosylations, which happen outside of 
the Golgi secretory pathway, and they have been found to play important roles in PTM and 
regulation such as in cell viability and nutrient sensors.24-26  
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Figure 1: Monosaccharides used in glycosylation. 
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1.1.2 Glycosylation function/importance 
Glycosylation products, comprised of glycoproteins, glycolipids and proteoglycans, 
play key roles in a wide variety of biological processes including cellular adhesion, cell 
signaling, cell-cell communication, and the immune response.27-29 For example, changes 
in glycosylation on Asn in Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) 
has been shown to be a main contributor to the biochemical activity of TAFIa.30 In addition, 
immune system responses can be directed by various specific site recognition mechanisms 
such as the recognition of  key linkages on sialyl Lewis X (sLex).31 In a similar manner, 
the body is able to recognize self from non-self and initiate appropriate immune responses 
through the discrimination of glycans expressed by pathogens compared to those of host 
cells.32,33 For example, glycans and glycoconjugates comprise part of a vast array of 
pathogen associated molecular patterns (PAMP), which once recognized and bound can 
initiate phagocytosis by Mϕs to rid the body of invading organisms.34-36 Furthermore, 
glycosylation plays a significant part in cellular receptor activation and signal transduction 
pathways.  As evidence of this, research has shown regulation of fucose specific 
transferases during embryonic neuronal development can be altered with development of 
O-fucose derivatives.37 The aforementioned examples only highlight some of the different 
areas of importance as far as glycosylation is concerned emphasizing the need for glycan 
sensing and study.  
     Given the importance of glycosylation in normal physiological functions, it is not hard 
to understand the dysfunction and disease that could result from abnormalities in certain 
glycosylation patterns. For example, the congenital disorders of glycosylation in children,  
refer to a large number of syndromes including severe morphogenic and metabolic defects 
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associated with general failure to thrive, most of which have been linked to distinct steps 
in glycan formation.38-40 Defects in protein catabolism are also caused by glycosylation 
abnormalities. More specifically, in the case of  I cell disease, failure to produce 
the mannose 6-phosphate modification on N-glycans in the Golgi results in a loss of signal 
transduction necessary for trafficking of hydrolases to the lysosome leading to a storage 
disorder.41,42  
Glycans have additionally been recognized as biomarkers for certain types of 
pathological conditions such as cancer.43-46 Increased expression and/or modifications to 
typical linkages can occur such as O-acetylation can either disappear, as in colon cancer, 
or become more prominent as in the case of melanomas and basal cell carcinomas.47-49 
Overexpression of particular glycans may also enhance the masking effect of abnormalities 
inhibiting the immune response. Even with well documented glycosylation related 
diseases, the discovery process is more serendipitous than well planned.15 Common 
methods for protein separation are not able to catch small variations in glycosylation, 
making the development of such tools vital to a better understanding glycosylation and its 
implications. 
1.1.3 Traditional tools and methods for glycosylation studies 
Traditional analytical approaches for determination of unique primary glycan 
structures include but are not limited to tandem high pressure liquid chromatography 
(HPLC), mass spectrometry (MS),50-52 and nuclear magnetic resonance (NMR).53,54 Even 
with the power and proven versatility of these traditional methods they still suffer from 
their individual drawbacks.  These include time consuming optimization, experience 
needed to perform experiments, and large sample amounts in the case of NMR. In addition 
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to the methods/instruments themselves, the ability to remove saccharides from 
bioconjugates and purify them for characterization is a difficult science. Because of glycan 
heterogeneity and the time consuming nature of sample preparation, systematic analysis of 
a large number of complex glycans demands a more efficient approach.  
Lectin microarrays have also see widespread use in glycosylation research over the past 
few years.55,56 Essentially, lectins are immobilized onto an array surface and analytes with 
fluorescent tags are applied to the microarray. After washing any unbound analytes from 
the array the fluorescent signals are analyzed and a specific glycosylation pattern is 
obtained. Using this method, information such as glycosidic linkages and monosaccharide 
content can be ascertained. Even with lectin microarrays widespread use, lectins 
themselves suffer from one fundamental drawback and that is the number of available 
lectins. There are hundreds of thousands of glycan and glycoconjugate combinations but 
only about 40 easily available commercial lectins. Another drawback to using lectins is the 
cost of using biological generated lectins greatly outweigh the cost of chemically 
synthesized lectins. 
1.2 Sialic acid 
The surfaces of all vertebrate cells in nature are comprised of a variety of 
glycoconjugates including glycoproteins, proteoglycans and glycolipids forming the 
cellular glycocalyx.57,58 SA moieties are typically located at the terminal position of these 
glycoconjugates are known as “decorations” providing extreme structural and functional 
diversity (Figure 2).59 The two major SA core structures are 2-keto-3-deoxynononic-acid 
and neuraminic acid sharing nine carbons and differing at the C5-position (                     Figure 
3). The variety of substituents on carbon 4, 5, 7, 8 and 9 generate a diverse family of more 
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than 50 structurally distinct molecules, which can be attached to underlying sugars, 
commonly via α-2,3 or α-2,6 linkage to Gal, via α-2,6 linkage to GalNAc or GlcNAc, or 
via α-2,8 linkage to another SA.60-62 N-acetylneuraminic acid (Neu5Ac) is the most 
frequent form followed by N-glycolylneuraminic acid (Neu5Gc) and O-acetylated 
derivatives. Among mammals, humans are a known exception in their lack of Neu5Gc, due 
to an inactivation mutation in a hydroxylase, which modifies CMP-Neu5Ac to CMP-
Neu5Gc.63,64  
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Figure 2: Complexity of SA layer on the cell surface. Adapted from 
reference 61 
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                     Figure 3: Diversity of SA structures and linkages. 
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Given SAs terminal location and remarkable diversity in structure, glycosidic linkages, 
and underlying glycan chains, it is not surprising that SAs act as intermediaries in a wide 
variety of physiological and pathological processes. These processes include 
immunomodulatory effects, hormonal responses, signal transduction, tumor progression, 
cell adhesion and protection.59, 65-67 SAs negative charge and hydrophilicity allow it to act 
as an anti-recognition agent, masking recognition sites such as Gal residues, antigenic 
proteins and receptor molecules.68,69 SAs duality allows it to act simultaneously as a 
recognition site for a particular subset of proteins called lectins. Lectins are glycan 
recognition proteins that lack any enzymatic activity on their substrate. Angata et al. 
proposed to group lectins into three categories: pathogenic lectins, endogenous lectins, and 
lectins from other sources such as plants and protostomes.62 
1.3 Lectins 
As previously mentioned, proteins capable of interaction with carbohydrates are termed 
lectins. These types of non-covalent interactions occur widely throughout nature and 
include carbohydrate specific enzymes and antibodies formed as part of an immune 
response to carbohydrate antigens. The term lectin originates from Latin meaning “to 
select” or “choose” owing to their high specificity.70-72 Lectins are defined as a class of 
carbohydrate binding proteins that can recognize and bind carbohydrates reversibly but 
without any catalytic activity.73 Lectins exist in most organisms ranging from viruses and 
bacteria to plants and animals. Concanavalin A, the first purified lectin, was isolated by 
Sumner in 1919, who also demonstrated its carbohydrate specificity.74 It was later 
determined that lectins could play a crucial role in blood group identification.75 Currently, 
lectins are widely used to investigate cell-cell recognition events as well as the study of 
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carbohydrates on the cell surface.  
Each lectin molecule is typically multivalent having two or more carbohydrate binding 
sites. Because of this feature, interactions involving cell surface glycans, or 
glycoconjugates, can result in the cross linking of cells resulting in precipitation. Indeed, 
this phenomenon is referred to as agglutination and is routinely used for the detection and 
characterization of cell surface glycoconjugates. As a method of control, these 
agglutination processes can be inhibited by the addition of those saccharides that each 
lectin shows affinity towards. Lectin affinity for monosaccharides is generally considered 
weak (Kd = mM range), however highly selective, meaning, lectins specific for Man do not 
react with Glc, nor do those specific for Gal bind Glc. Cooperative multivalent interactions 
of lectins towards oligosaccharides changes their dissociation constant to the Kd = μM 
range, while lectin-monosaccharide interactions remain unchanged.76,77 However, the 
selectivity of lectins for monosaccharides is not always so high.  
Lectin-glycan binding affinity is quite structure dependent and saccharides with 
different chemical compositions but similar topographic properties can bind to the same 
lectin.78 In contrast, different lectins for the same saccharide could focus on separate 
regions of the saccharide structure. However, once bound by lectins, specific conformation 
of the glycan is locked and fixed and the rotational freedom around glycosidic linkage is 
reduced. Thus, lectins bind saccharides in a reversible and specific way, but they all have 
cross-reactivity issues to some extent.78,79 Subsequently, some lectins are glycosylated and 
endogenous lectins could interact with the glycans on the surface of the lectin probe.80 In 
conclusion, lectins high specificity and participation in physiological processes such as cell 
adhesion, cell trafficking and signal transduction make them among the most widely used 
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tools in glycan research despite their drawbacks.  
1.3.1 Animal lectins 
So far, three major classes of natural glycan binding proteins (GBPs) have been 
identified in mammalian systems and consist of 4 subgroups: 1) the S-type lectins; 2) the 
C-type lectins; 3) the P-type lectins; and 4) I-type lectins.78 The S-type lectins, called 
galectins, are found inside the cytoplasm, the nucleus, on the cell surface, and outside the 
cell. The galectins are defined by their selective affinity towards Gal containing ligands on 
the cell surface.81-83 More than ten mammalian galectins have been identified as well as 
other from such sources as birds, amphibians, and fish.84 Galectins mediate such 
physiological processes such as  cellular communication, inflammation, development, and 
differentiation.85-87  
The C-type lectins are so named because of their dependence on Ca2+ for proper 
function. C-type lectins can be divided further into three subclasses: endocytic lectins, 
collectins and selectins.88 Endocytic lectins are transmembrane proteins with an 
extracellular carbohydrate recognition domain (CRD) specific for the Gal/GalNAc 
moiety.89,90 In contrast, collectins are soluble proteins with a cysteine-rich amino terminal 
and a CRD carboxyl terminal.91,92  
P-type lectins are distinguished from all other lectins by their ability to recognize 
phosphorylated Man residues. P-type lectins play an essential role in intracellular 
trafficking and the generation of functional lysosomes by directing newly synthesized 
lysosomal enzymes bearing the mannose 6-phosphate signal to lysosomes.60, 93 
The I-type lectins, also called selectins or siglecs, are comprised of three cell surface 
glycoproteins called Endothelial (E-), Leukocyte (L-) and Platelet(P-) selectins which 
  13 
participate in many cell-cell interactions in immunity, hemostasis, and inflammation. E- 
selectins recognize SAs on leukocytes and mediate the adhesion of leukocytes to activated 
endothelial cells.94 P-selectins also mediate adhesion to SA containing ligands on 
leukocytes, migrating quickly in response to various stimuli.95 Lastly, L-selectins can 
recognize sialylated ligands within the endothelium and facilitate migration of cells into 
the lymphatic system.96 
1.3.2 Plant lectins 
Plant lectins are like animal lectins and exhibit high specificity and some can 
distinguish isomeric glycans within identical glycan compositions. For example, Sambucus 
nigra agglutinin (SNA) binds to SA linked to either Gal or GalNAc via α-2,6 linkage and 
Maackia amurensis (MAA) recognizes α-2,3 linked SA.97 Most plant lectins belong to the 
legume family and their specificity is owed to highly conserved binding sites consisting of 
four invariant amino acids: aspartic acid, asparagine, a glycine, and an aromatic amino acid 
or leucine. The binding site architecture is typically derived from four loops designated A, 
B, C, and D.98 Loop A and B consists of the aspartic acid and glycine residues which are 
invariable and asparagine and the hydrophobic area make up loop C. Loop D, however, is 
highly variable having differences in length, sequence, and conformation meaning there 
are additional interactions and specifications for monosaccharides. What can be noted, is 
that loop D often exhibits identical properties among similar lectins. For example, loop D 
is identical in size for all Man specific lectins.99  
1.3.3 Sialic acid specific lectins and their applications 
Cell surface SAs, sialoglycans, and their modifications can be detected by the use of 
lectins in what can be referred to as bio-affinity recognition; the exploitation of biological 
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sample affinities. As previously mentioned, SA-specific lectins are particularly helpful 
because of their ability to discriminate between complex sialylated glycans and 
glycoconjugates on the cell surface. So far, fluorescently labelled lectins have been widely 
used to analyze the sialoglycoconjugates in histochemistry, lectin-microarrays, flow 
cytometry, and microscopic analysis (Table 1). 
Lectin-histochemical staining offers detailed information about the occurrence and 
distribution of SA residues in tissues and in different types of biological samples.100 
Recently, lectin-histochemical staining has been used to study cancer, in which aberrant 
expression of sialoglycoconjugates is thought to play an important role in cancer 
progression.101,102 SNA and Maackia amurensis leukoagglutinin (MAL), with their ability 
to discern between α2,6-linked and α2,3-linked SA residues respectively, have been 
effectively used for biochemical and histochemical analyses of sialoglycoconjugates.103 
Studies were first conducted comparing the expression of α2,6-linked SAs by SNA-
digoxigenin staining of histological sections104 followed by the use of biotinylated MAL 
in the investigation of the pathological significance of sialylation in colorectal cancer and 
gastric cancer.105,106 In these studies, the sialoglycoproteins in gastric cancer tissues were 
analyzed using MAL in combination with 2-dimensional electrophoresis. Various MAL-
positive sialoglycoproteins were detected in cancer tissues in comparison to healthy 
individuals suggesting the MAL-positive sialoglycoproteins detected in gastric cancer 
tissues have high molecular weights and may contain different numbers of α2,3-linked SA 
residues in the glycan moiety.106 Recently, the clinical pathological feature of several types 
of sialylated glycoconjugates in colorectal cancer have been compared in regards to their 
expression levels using biotinylated MAL, Sambucus sieboldiana, and MAA.107 It was 
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found that α2,3-sialylated type 2 chain (NeuAcα2,3Galβ1,4GlcNAcβR) structures were 
predominantly expressed in colorectal tissues associated with malignant transformation, in 
particular, with lymphatic spread of distal colorectal adenocarcinomas.  
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Table 1: SA-specific binding lectins. 
 
Lectin (Origin) Specificity References 
ACG (Agrocybecylindracea)  Neu5Ac(α2,3)Gal, β-Gal 108 
MAH (Maackia amurensis 
hemagglutinin)  
Neu5Ac(α2,3)Gal  109-111 
MAL (Maackia amurensis 
leukoagglutinin) 
Neu5Ac(α2,3)Gal 111-115 
MPA (Macrophomina 
phaseolina agglutinin) 
Neu5Ac(α2,3)Gal  116 
PSA (Polyporussquamosus) Neu5Ac(α2,6)Gal 117-118 
PVL (Psathyrellavelutina)  Neu5Ac(α2,3)Gal, GalNAc 119 
SCA (Sambucus canadensis) Neu5Ac(α2,6)Gal/GalNAc 120 
SNA (Sambucus nigra) Neu5Ac(α2,6)Gal/GalNAc 121,122 
SSA (Sambucus sieboldiana) Neu5Ac(α2,6)Gal/GalNAc 123 
Saracin (Saracaindica) Neu5Ac(α2,6/3)Gal1-4GlcNAc 124 
TJAL (Trichosanthes 
japonica) 
Neu5Ac(α2,6)Gal/GalNAc, 
HSO3(-)-6Gal1-4GlicNAc 
125 
WGA (Wheat germ 
agglutinin)  
Neu5Ac, GlcNAc(β1,4)GlcNAc 126,127 
ML-1 (Viscum album) Neu5Ac(α2,6)Gal1-4GlcNAc 128 
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Flow cytometry is a powerful tool for the analysis of individual cells within 
heterogeneous populations. In 2002, Lin et al. examined the effect of α2,6-sialylation on 
the adhesion properties of breast carcinoma cells with different levels of an expressed 
sialyltransferase ST6Gal-I.129 It was discovered by using lectins to quantify cell surface 
sialylation that cellular adhesion of tumor cells was regulated by α2,6-sialylation 
expression levels. In another study, the expression levels of α2,3-linked SA residues were 
measured in human gastric adenocarcinoma cell lines by using fluorescein isothiocyanate 
(FITC)-labeled MAL indicating a high level α2,3-linked SAs is associated with the 
metastatic potential of human gastric cancer.130 
Both flow cytometry and confocal microscopy have also shown cell surface α2,3-linked 
SAs were predominant under normal culture conditions and changed slightly upon 
activation with atorvastatin, while α2,6-linked SA abundance was minimal under normal 
conditions, increasing significantly increased upon activation with atorvastatin (Figure 
4).131 These results provide a closer look at the role SAs play in biological functions of the 
cells upon activation. 
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Figure 4: Confocal microscopy analysis of cell surface SAs. (I) (A) Raw 
264.7 cells at the normal culture condition stained with MAA-FITC (10 
μg/mL) and SNA-FITC (20 μg/mL), respectively. DAPI was used to stain 
nuclei. (B) Raw 264.7 cells treated with 20 μM atorvastatin for 24 h 
followed by staining with lectins and DAPI. The scale bar represents 10 μm. 
(II). Determination of cell surface SAs by flow cytometry: (A) Raw 264.7 
cells at normal condition stained with MAA-FITC (10 μg/mL) and SNA-
FITC (20 μg/mL), respectively. PI staining was used to distinguish living 
cells and dead cells. (B) Raw 264.7 cells were treated with 20 μM 
atorvastatin for 24 h then stained with lectins and PI. Adopted from 
reference 131 with permission from Oxford University Press. 
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1.4 Boronic acid 
As outlined above, glycomics requires ongoing investigation into novel tools to support 
and complement current biological approaches. In an ongoing effort to use biology driven 
methods, there has been a concerted effort to develop artificial sensors for carbohydrates. 
These synthetic and artificial sensors, termed lectin mimetics, will undoubtedly find their 
place in glycosylation research as well as clinical diagnostic and therapeutic applications. 
In general, there exists two methods when it comes to artificial sensor design strategy: 
boronic acid based and non-boronic acid based. The nature of biological research and 
clinical diagnostics makes water a primary requisite for carbohydrate sensing methods. 
This effectively eliminates non-boronic acid based mimetics, as most only function under 
an aprotic solvent relying primarily on hydrogen bonds along with hydrophobic and ionic 
interactions.132,133 In contrast, boronic acid-based lectin mimetics work well in aqueous 
media and rely on strong reversible interactions between boronic acids and accessible diol 
moieties.134 
1.4.1 Boronic acid chemistry 
Boronic acid is widely acknowledged by chemists for its ability to react with 1,2 and 
1,3 diols in aqueous media through reversible boronate ester formation (Scheme 1).135-137 
To discuss boronic acid-carbohydrate complexation there are several fundamental aspects 
that must be understood. Boronic acid, using phenylboronic acid as an example (Scheme 
1, 1), acts as a Lewis acid accepting a lone pair of electrons from a protic solvent such as 
water (Scheme 1, 2). These electrons cause the hybridization state to change from sp2 to 
sp3. The second step is boronic acid’s reaction with a diol to form a boronate ester (Scheme 
1, 3). At this point, the boronate ester is still considered acidic and can react with a protic 
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solvent molecule, releasing a proton, and forming the negatively charged tetrahedral 
boronate complex (Scheme 1, 4). Lastly, it must be understood that because of the inherent 
acidity of both the boronic acid and its corresponding ester, binding can be affected by pH 
and individual pKa values. Most of the time ideal binding involves using a pH that falls in 
between the pKa of the boronic acid and that of the diol.138 There are also additional factors 
that may play a role in the unique binding profiles of boronic acids including solvent 
system, buffer composition, temperature, and steric hindrance.139 
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      Scheme 1: Binding of phenylboronic acid with a diol. 
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In conclusion, the basic chemistry of boronic acid and some fundamental features of 
the boronic acid-diol binding process have been discussed. Hopefully, this provides a good 
foundation for the rational design and synthesis of boronic acid-based carbohydrate 
sensors.  
1.4.2 Molecular boronic acid as a carbohydrate sensor 
`Due to the recent boom in glycobiology and glycomics, carbohydrate research has 
been recognized an area of enormous untapped biological potential. The diversity and 
complexity of glycan structures, together with their crucial role in many physiological or 
pathological processes, requires the development of new tools that allow for high affinity 
and specificity recognition events. Since their recognition over a century ago, boronic acid 
has been exploited extensively as chemo/biosensors in the detection of carbohydrates.136, 
139-141 Now, the boronic acid-diol interaction may be one of the most widely used single 
pair functional groups in the design of sensors and binders.79, 142 Boronic acid sensors are 
typically, an organic molecule conjugated to a fluorophore used to analyze a signal 
generated after interaction with the analyte of interest. Although glycans and 
glycoconjugates differ on a macroscopic and microscopic scale, the main difference is the 
spatial arrangement and orientation of hydroxyl groups. Because of the various 
configurations, it can be difficult to detect analytes with good selectivity using a 
unimolecular model. For this reason, more than one boronic acid group has been introduced 
into molecules to afford multivalency, mimicking molecular recognition in biological 
systems.143,144 Multivalent interactions require the existence of more than one binding site 
on both the receptor and analyte. This provides a synergism between multiple weak 
interactions resulting in a higher affinity. For example, in 2002, Wang et al., designed and 
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synthesized a series of fluorescent bisboronic acid sensors by changing the linker between 
the bisboronic moieties for the detection of sLex. Among the synthesized compounds was 
on that showed a strong affinity for sLex in comparison to the control which was not labeled 
in the experiment.145  
In conclusion, molecular boronic acid derivatives have seen widespread use and proven 
their versatility in glycomics research. One of the most difficult challenges is the design of 
a proper scaffold to orient the boronic acid moiety in the proper manner to afford the 
desired specificity and selectivity. Unimolecular boronic acid-diol interactions are too 
weak by themselves and multivalent molecules show much higher promise regarding 
higher affinity and selectivity. As a complement to the time-consuming method of de novo 
design and template directed synthesis, combinatorial libraries may help to overcome the 
limited availability of carbohydrate sensors and lectin mimetics. In an extension of this 
research, other groups have begun to attach boronic acid to larger molecules, offering an 
increase in number of available binding sites, altered orientation and spatial arrangement 
and have coined the term “boronolectin”, referring to all boronic acid derived carbohydrate 
sensors.79, 139, 146  
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Figure 5: Structure of compound 1 and fluorescent labeling study. sLex 
expressing HepG2 cells (bottom) and non-expressing sLex COS-7 cells 
(top). Adopted from reference 134 with permission from The Royal Society 
of Chemistry.  
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1.5 Boronolectins 
One of the biggest challenges in designing carbohydrate sensors is the construction of 
the three-dimensional framework to obtain the desired affinity and specificity toward a 
given glycan. Using polymers, dendrimers, proteins, and other larger molecules has 
afforded not only an increase in multivalency but also provides functional groups for 
complementary interactions. In addition, using these types of molecules also provides 
opportunities to perform combinatorial work while permitting the use of various 
macromolecular conformations. 
1.5.1 Polymer based boronolectins 
Boronate containing polymers (BCPs) have gained increasing attention over the last 
ten years ranging from water soluble synthetic polymers, to micelles, and polymeric 
brushes.147,148 Because of their affinity towards saccharides in aqueous solutions BCPs 
have been widely used and studied for sugar sensing, drug delivery, pharmaceutical assays, 
purification, and recently for gene transfection.149 Since natural lectins had previously 
showed promising activity as mucosal adhesive reagents, it seemed advantageous to some 
groups to use BCPs as an replacement.150-152 Despite previously discussed drawbacks to 
lectins and lectin-mimetics, BCPs recognition of polysaccharides of mucin in aqueous 
solutions has been proven and multiple materials have been developed. For example, 
contact lenses containing BCPs on their surface were prepared by free radical 
polymerization.153 The affinity of the polymer-coated lenses to mucin was proven by an 
enzyme-linked lectin assay: biotinylated jacalin, a Gal-binding lectin, was found to adsorb 
to the mucin-treated lenses as expected. This allows the contacts to bind mucins with the 
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tear film mitigating dry eye, while providing additional protection again bacterial, chemical 
and physical invasion.153    
1.5.2 Dendrimer based boronolectins 
Dendrimers are typically highly symmetric monodisperse molecules that comprise a 
subset of highly branched polymers. While the simplest linear chain BCPs have their own 
set of unique qualities, dendrimeric boronic acid functionalized molecules create an 
additional type of multivalent molecule. The Liu group for example, proposed a synthetic 
model for the enrichment of trace glycoproteins using magnetic nanoparticles as a solid 
support for the generation of multiple generation Poly(amidoamine) (PAMAM) 
dendrimers (generation 4.0, G4, 64 surface amino groups) functionalized with boronic acid 
(Figure 6). PAMAM dendrimers were chosen as the main scaffold due to its unique 
properties, plentiful functional groups, and easy modification. Notably, the magnetic core 
is not involved in the binding with glycoproteins. Using 3 representative glycoproteins with 
molecular masses of 44, 80, and 150 kDa, and each with its own carbohydrate makeup, 
they compared the binding strength between nanoparticles and each glycoprotein as well 
as the dendrimeric model to non-dendritic nanoparticles. The results of the experiment 
showed a synergistic quality of the dendrimer based molecules enhancing avidity towards 
glycoproteins 3-4 times higher than the boronate affinity of single binding events. As 
proposed, the improved binding strength allowed higher efficiency of low concentration 
glycoproteins as well as being tolerant of competing glycans.154 Based on this work it can 
be said that this strategy can be applied to other types of boronic acid and other types of 
solid supports, thereby making combinatorial chemistry more resourceful.  
  27 
 
Figure 6: Boronic acid functionalized magnetic nanoparticles. Adopted 
from reference 154 with permission from MDPI. 
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1.5.3 Nucleic acid based boronolectins 
In an ongoing effort to increase the number of boronic acid derivatives, there has been 
extensive research into the use of nucleic acid products. For example, the Anslyn group 
developed unmodified ribonucleic acid (RNA) to selectively tune a small molecule 
carbohydrate receptor155 and the Yu group developed RNA aptamers for sLex detection.156  
Aptamers are single-stranded oligonucleotides able to bind small molecules, 
macromolecules or whole cells.157 Anslyn’s group successfully demonstrated the capability 
to use unmodified RNA aptamers to modify the selectivity of a boronic acid based receptor. 
Initially, a bis-boronic acid derivative (Figure 7,1) was known to preferentially bind citrate 
at Kd = 5.5 x 10-6 M-1 compared to tartrate at Kd = 7.1 x 10-6 M-1. After immobilization onto 
agarose beads (Figure 7, 2), the boronic acid derivatives were subjected to an RNA pool in 
the presence of tartrate followed by systematic evolution of ligands by exponential 
enrichment (SELEX). Fundamentally, SELEX is a method that relies on the high affinity 
of a binding ligand to recognize high affinity RNA from a randomized pool of RNA. 
Enrichment performed over multiple “rounds”, results in the ability to separate bound RNA 
from unbound RNA.158 As a result, tartrate binding was found to increase when the RNA-
receptor was involved. In the presence of one of the 7 aptamers tested, the Kd for citrate 
changed to >3 x 10-3 M-1 and the Kd for tartrate changed to 2.1 x 10-4 M-1, or in other words 
a 14-fold higher biding constant for tartrate over citrate. In comparison, in the absence of 
the aptamer the receptor had a 1.3-fold higher preference for citrate over tartrate.155 
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Figure 7: Bis-boronic acid, and its immobilized form. Adopted from 
reference 155 with permission from American Chemical Society. 
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1.5.4 Protein based boronolectins 
Protein based boronolectins have recently been investigated for use as intracellular 
probes and therapeutic agents. One major challenge is the ability to direct proteins or 
therapeutic agents to the site of action. Based on carbohydrate sensing abilities this 
challenge could possibly be overcome using boronic acid derivatized proteins. It is well 
known that certain cancers over express SA and the targeting of such has been exploited in 
recent years.159,160  
This section will focus on the use of boronic acid to extend the half-life of a drug while 
mitigating detrimental effects and acting as a glycan sensor. Among the  list of medications 
for treating diabetes, insulin therapy remains the number one option for both palliative and 
preventative purposes.161-163 One drawback to the use of insulin is that treatment is self-
administered. This inevitably leads to dosage control issues leading to hypoglycemia that 
can be fatal. By minimizing the frequency of self-administration, the number of 
hypoglycemic incidents would undoubtedly decrease. Long acting insulin variants as 
opposed to native unmodified or fast acting types could reduce self-administration 
frequency by what can be considered tunable pharmacokinetics.164,165 
The Anderson group, has succeeded in creating what could be called a “smart” long 
acting insulin, responsive to Glc, based on a boronic acid modified insulin. Multiple 
derivatives  of human insulin were investigated and the best performing derivative could 
lower blood Glc levels and provide glycemic control compared to native insulin. The rate 
of hypoglycemia was reduced compared to native insulin as well. These studies were done 
using a human insulin derivative without BA as a positive control.146, 166,167 
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1.6 Glycopolymers as glycomimetics 
In contrast to studying lectins and lectin mimetics is another area of research concerned 
with explaining the appealing selectivity of protein-glycan interactions. In this regard, 
glycopolymers, typically polymers with glycan pendant groups, have been extensively 
explored as multivalent carbohydrate for probing carbohydrate-protein interactions in an 
effort to gain a better understanding of their underlying mechanisms.168 For example, 
glycopolymers can act as agonists or antagonists for understanding the molecular 
mechanisms of many biological processes, and also provide tremendous opportunities for 
therapeutic applications. In addition, glycopolymers can serve as potential receptors for 
biochip/biosensor development, which can be used for understanding carbohydrate-protein 
interaction, substrate specificity of carbohydrate-processing enzymes, antibody profiling, 
biomarkers, and pathogen and toxin identification applications. Therefore, design and 
synthesis of glycopolymers has become a very important research field, where significant 
efforts are needed to develop advanced glyco-polymeric architectures with improved 
performance.169 
The precision in the design of synthetic glycopolymers - including chain composition, 
monomer sequence and architecture - has vital importance when it comes to mimicking the 
chemical and biological functions of glycoproteins. In addition, the glycan attachment to 
the polymer backbone is essential for its performance but has been paid little attention until 
now. So far, most glycans were attached to the polymer backbone through O-linked spacers 
or N-reductive amination-linked spacers, however, neither is a native glycan-amino acid 
linkage on glycoproteins, which may be a reason for the lower performance of 
glycopolymers.170 
  32 
The synthesis of glycopolymers is still challenging since it often requires multistep 
synthetic routes. A procedure in the synthesis of glycopolymers begins with the synthesis 
of a glycomonomer with a functional group at the anomeric position of the saccharide that 
can take part in subsequent polymerization reactions. Alternatively, the attachment of 
glycosyl derivatives to the pre-synthesized polymer is often used. Protection and 
deprotection of hydroxyl groups on the saccharide moieties are often necessary in either 
glycomonomer or glycopolymer synthesis requiring multistep synthesis and purification 
processes and is both costly and time consuming. Therefore, ongoing research into 
straightforward synthesis of glycopolymers void of multistep synthesis and purification 
techniques and without the need of protecting groups is greatly needed. 
One example of the use of glycopolymers as a glycomimetic (GM) is demonstrated by 
Oomen et al. The group successfully synthesized gold nanoparticles (Au-NP) coated with 
a fucose rich sulfated polysaccharide (fucoidan) mimetic glycopolymer (FMG) resembling 
heparin, that exhibited differential cytotoxicity toward colon cancer cells (HCT116) and 
were non-toxic to mouse fibroblast cells (NIH3T3). The FM glycopolymer alone was non-
cytotoxic to either cell type indicating the FMG-Au-NP preferential induction of apoptosis 
in colon cancer cells. In conclusion, this experiment showed fucoidan GMs increased the 
cytotoxicity of Au-NPs towards HCT116 cells while remaining non-cytotoxic 
themselves.171  
1.7 Aims and contributions of this dissertation 
The aim of this dissertation research is to synthesize new boronic acid containing lectin 
mimetics (BCL) as well as glycopolymers for use as GMs. Ideally, the BCLs should bind 
the abundant and often terminal SA residues on the cell surface while both BCLs and GMs 
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should elicit a cellular response. It was determined that a combinatorial library would be 
the best and most efficient approach eliminating the need for extraneous planning and 
design of materials. The work described in this dissertation consists of the following three 
key parts: 
A.  Investigating the regioselectivity of boronic acid  
A one-pot method for derivatization and methylation of glycans with 3-
aminophenylboronic acid (PBA) under basic conditions has been investigated.  Due to the 
specificity of PBA, a site-specific permethylation proceeds for galactopyranoside, 
mannopyranoside, and glucopyranoside as confirmed by 1H, 13C NMR, and MS. This 
research proposes both a novel and viable method for glycan analysis and elucidates 
specificity of PBA. 
B.  Boronic acid derived proteins as lectin mimetics  
The utility of BSA-PBA conjugates as successful glycan recognition molecules, to be 
used as lectin mimetics, has been demonstrated. The conjugates can be synthesized in a 
density controlled manner using traditional N-(3-(dimethylamino)propyl)-N-
ethylcarbodiimide hydrochloride (EDC) coupling techniques affording amide derivatives 
from carboxylic acid residues within the BSA protein structure. Additionally, the boronic 
acid conjugated proteins were immobilized onto maleimide functionalized silica gel via 
thiol–maleimide interactions and used to study the sugar binding specificity of several 
sugars by Alizarin Red S (ARS) displacement assay. Evaluation of biocompatibility using 
a 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed no 
effect on cell viability after 24 hours. Lastly, cellular studies confirm binding of BSA-PBA 
conjugates to the cell surface based on the inhibition of lectin-FITC binding. These lectin 
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mimetics will provide an important tool for future glycomics and biosensor research and 
applications. 
 C.  Glycopolymers as glycomimetics  
A straightforward synthesis of N-glycan polymers via acryloyl-glycosylamine and 
direct polymerization from free saccharides in aqueous conditions without 
protection/deprotection steps has been demonstrated. These glycopolymers have shown 
low levels of cytotoxicity based on multiple methods. In addition, immunomodulatory 
responses have been studied and significant differences seen based on the glycopolymer 
used in comparison to controls. 
In conclusion, the weak and therefore reversible nature of boronic acid binding makes 
it a prolific source of molecular recognition events, especially when combined with 
polymeric materials. Conversely using GMs to study carbohydrate sensing may help to 
better understand the mechanisms that act as a driving force, while at the same time may 
elicit their own responses needing further investigation. Research efforts in both areas deal 
with the difficulty of structure complexity and the methods are now limited due to the 
natural number of each of these materials. This places a significant amount of pressure on 
the carbohydrate community to develop more bio-mimetics with versatility, affinity, and 
specificity in mind. 
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CHAPTER 2 
REGIOSELECTIVITY OF BORONIC ACID-GLYCAN BINDING 
(CARBOHYDRATE PERMETHYLATION CHARACTERISTICS IN THE 
PRESENCE OF BORONIC ACID) 
2.1 Introduction 
Due to the recent boom in glycobiology and glycomics, carbohydrate research has been 
recognized an area of enormous untapped biological potential. The diversity and 
complexity of glycan structures, together with their crucial role in many physiological or 
pathological processes, requires the development of new tools that allow for high affinity 
and specific recognition events. Since their recognition over a century ago, boronic acid 
has been exploited extensively as chemo/biosensors in the detection of carbohydrates.1-4 
Now, the boronic acid-diol interaction may be one of the most widely used single pair 
functional groups in the design of sensors and binders.5,6 However, a clear understanding 
of the underlying chemical mechanisms regarding regioselectivity and binding site 
architecture is not well understood. 
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PBA was used as a glycan-binding reagent to determine its specific binding specificity 
and identify binding locations of gluco-, manno-, and galactopyranoside. The use of 
pyranosides (six membered rings) as a key recognition moiety was done for two reasons. 
First, pyranosides are known to generally have weak binding when compared to 
furanosides (five membered rings). Since the cell surface is mostly comprised of 
hexopyranosides it would follow that the studied sugars mimic these structures. Secondly, 
because the cell surface glycans are linked, most of them have non-reducing ends, which 
are represented by a methyl group on the pyranosides. It was clear from the beginning that 
if the use of boronic acid receptors is to mature into a general approach for saccharide 
recognition, new boronic acids with pyranoside-binding capability was required for the 
preparation of boronate conjugates. In this study, a one-pot method was developed for the 
determination of regioselectivity of PBA regarding glycopyranoside binding. PBA was 
conjugated to gluco-, galacto- and mannopyranosides followed by methylation, both 
reactions taking place under basic conditions (Scheme 2). Based on boronic acid specificity 
towards cis-diol configurations, a unique permethylation pattern was observed for each 
glycan and was characterized by 1D/2D NMR and mass spectrometry. 
2.2 Materials and methods 
Unless otherwise noted, all solvents and reagents were purchased from commercial 
sources and were used as received. Solvents were purified by standard methods prior to 
use. Deionized water with a resistance of 18M cm-1 was used as a solvent in all reactions 
and purification experiments. 1H and 13C NMR spectra were recorded at room temperature 
with a Bruker AV400 MHz spectrometer and DMSO was used as deuterated solvent. TLC 
analysis was performed on silica gel plates and column chromatography was conducted 
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using silica gel (mesh 230− 400), both of which were obtained from Silicycle, Ultrapure 
silica gels (Quebec, CA). 
2.2.1 Conjugation and permethylation 
Each pyranoside (Scheme 2, 1a-c) (100 mg, 0.5 mmol) and PBA (80 mg, 0.5 mmol) 
was dissolved in  NaHCO3 buffer (2 mL, 100mM, pH = 8.6) and stirred overnight at room 
temperature. The solution containing product (Scheme 2, 3) was washed three times with 
MeOH to remove buffer salts and dried by lyophilization.  
Permethylation of (Scheme 2, 3) was carried out by adding dry sodium hydroxide 
(NaOH) and iodomethane (CH3I). NaOH (50% w/v, 200μL) to high pressure liquid 
chromatography (HPLC) grade MeOH (400 μL) to prepare the base. Anhydrous dimethyl 
sulfoxide (DMSO, 4 mL) was added and the mixture centrifuged at 2000 rpm for 1 min 
before removing the supernatant and the procedure repeated 4 additional times. The 
DMSO/NaOH slurry (1 mL) was added to the dry conjugated product followed by 600 μL 
of base and 150 μL CH3I. The sample was vortexed for 10 minutes and washed 3 times 
with 2 mL NaHCO3 buffer. The organic layer was discarded and the aqueous layer was 
dried by vacuum.  
Cleavage of the PBA from the derivatized glycan (Scheme 2, 4) was performed by 
dissolution in  0.3% formic acid  (1:1, H2O/MeOH) for 2 hours and dried by vacuum 
affording a crude mixture containing product (Scheme 2, 5). Scheme 1 outlines the general 
procedure performed. 
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2.2.2 Purification 
Following removal of the solvent, crude product (Scheme 2, 5) was purified by silica 
gel chromatography (Ethyl acetate (A) / Hexanes (B) = 4:1, v/v) to afford pure 
permethylated derivatives in approximately 40% yield. 
Purification of methyl-β-D-glucopyranoside (5a): Prepared as described for the 
general procedure. Yield: 43% (3.6 mg); linear A-B gradient from 80%-100% of A; 1H 
NMR (400 MHz, DMSO-d6) δ: 5.1385-5.1238 (d, 1H, 1 x OH-4), 4.5594-4.5297 (t, 1H, 
OH-6), 4.1689-4.1495 (d, 1H, H-1), 3.6876-3.6675(dd, 1H, H-6), 3.6580-3.6382 (dd, 1H, 
H-6’), 3.4766 (s, 3H, 3-OCH3), 3.4190 (s, 3H, 2-OCH3), 3.4096 (s, 3H, 1-OCH3), 3.1953-
3.1350 (m, 1H, H-4), 3.1350-3.0761 (m, 1H, H-5), 3.0173-2.9733 (t, 1H,  H-3), 2.7868-
2.7447 (dd, 1H, H-2); ESI-MS: [M-H]- calcd for  C9H18O6, 221; found, 221. 
Purification of methyl-β-D-galactopyranoside (5b): Prepared as described for the 
general procedure. Yield: 38.6% (3.2 mg); linear A-B gradient from 80%-100% of A; 1H 
NMR (400 MHz, DMSO-d6) δ: 4.8708-4.8554 (d, 1H, 1 x OH-4), 4.5839-4.5718 (d, 1H, 
OH-3), 4.0965-4.0772 (d, 1H, H-1), 3.5633-3.5429 (t, 1H, H-5), 3.5284-3.4711 (m, 3H, 1 
x H-3, 1 x H-6, 1 x H-6’), 3.4139 (s, 3H, 2-OCH3), 3.3751 (s, 3H, 3-OCH3), 3.3547-3.3385 
(m, 1H, H-4), 3.2633 (s, 3H, 6-OCH3), 3.0073-2.9640 (dd, 1H, H-2); ESI-MS: [M-H]- 
calcd for C9H18O6, 221; found, 221. 
Preparation of methyl-α-D-mannopyranoside (5c): Prepared as described for the 
general procedure. Yield: 33.5% (2.8 mg); linear A-B gradient from 80%-100% of A; 1H 
NMR (400 MHz, DMSO-d6) δ: 4.8974-4.8869 (d, 1H, 1 x OH-2), 4.7758-4.7586 (d, 1H, 
OH-3), 4.4665-4.4628 (d, 1H, H-1), 3.5766 (t, 1H, H-2), 3.5294-3.4977 (m, 2H, 1 x H-3, 
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1 x H-6), 3.4008 (s, 3H, 6-OCH3), 3.3881-3.3475 (m, 1H, H-6), 3.2858 (s, 3H, 4-OCH3), 
3.2261 (s, 3H, 1-OCH3), 3.1962-3.1486 (t, 1H, H-5); ESI-MS: [M-H]- calcd for C9H18O6, 
221; found, 221. 
2.3 Results and discussion 
A novel method was used to determine the regioselectivity of BA in one-pot fashion 
under basic conditions. First, unique glycopyranosides, simulating physiological glycans 
were conjugated to PBA in aqueous media under basic conditions. Following conjugation, 
a permethylation reaction utilizing NaOH, CH3I, and DMSO was used to methylate 
reactive hydroxyl groups. Following the permethylation reaction PBA was cleaved from 
the sugar affording two hydroxyl groups previously unable to undergo methylation. 
Following purification by chromatography, purified products were analyzed by NMR and 
MS (Scheme 2, 5a-c).  
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Scheme 2: General synthetic procedure. (1) Conjugation of methyl-D-
glycosides with PBA (2) to form boronate conjugate (3) based on diol 
recognition. Permethylation with NaOH and CH3I to form (4) followed by 
cleavage of PBA with formic acid affording identifiable binding locations 
on each pyranoside (5). (Methyl 𝛽-D-glucopyranoside is shown as a 
representative glycoside for the procdure.  Methyl 𝛽-D-galactopyranoside 
and Methyl α-D-mannopyranoside were also used following the same 
procedure).  
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2.3.1 Mass spectroscopy 
Permethylation has been widely used to increase sensitivity and stability of glycans for 
characterization by MS. In this study, MS successfully confirmed permethylation products 
without the need for purification. The mass spectra for each pyranoside was obtained in 
negative electrospray ionization mode because of an amplified signal compared to positive 
mode. As seen in Figure 8, the derivatized product of methyl β-D-glucopyranoside shows 
an m/z ratio of 221[M-H]- , indicating the addition of two methyl groups (-CH2 = 14) 
compared to the expected value of 271 [M-H]- for the fully permethylated derivative or 
193 [M-H]-  for the starting material. This corresponds to boronic acid’s specificity towards 
1,2 and 1,3 diols and of the possible five potential binding sites, only two were observed 
to react, each corresponding to a particular glycan. 
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Figure 8: Representative ESI/MS chromatogram of Methyl 𝛽-D-
glucopyranoside (5a). 
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2.3.2 Nuclear magnetic resonance 
NMR characterization was carried out using 1D and 2D experiments including 1H, 13C, 
Correlation Spectroscopy (COSY), Nuclear Overhauser Effect Spectroscopy (NOESY), 
Heteronuclear Single Quantum Coherence (HSQC), and Heteronuclear Multiple Bond 
Correlation (HMBC). Characterization of the glucopyranoside product was used as a 
representation of the general method of characterization. Briefly, 3-5 mg of purified 
product was dissolved in DMSO-d6 and subjected to NMR spectroscopy. Figure 9, shows 
the 1H NMR comparison of glucopyranoside before and after derivatization. More 
specifically, the appearance of two –CH3 peaks between 3.4-3.5 ppm in Figure 2B, in 
comparison to Figure 2A, confirms both BA conjugation as well as success methylation of 
reactive protons. Figure 10B, 13C NMR further confirms the addition of two methyl groups 
with a total of three methyl peaks near 60 ppm compared to only one present in the Figure 
3A. With the presence of free hydroxyl groups at Figure 11A at 4.6 and 5.1 ppm the 1H 
NMR spectra gives correlations in the COSY to the protons at carbons 4 and 6, allowing 
the determination of methyl groups to be on carbons 1, 2, and 3. NOESY was used to 
further confirm peak assignments by showing spatial correlation between protons (Figure 
11). The arrows at 2.7, 3.0, 4.2 ppm indicate correlations between protons directly attached 
to carbons 1, 2, and 3 and the three corresponding methyl groups between 3.4-3.5 ppm.  
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Figure 9: 1H NMR, DMSO-d6, Methyl 𝛽-D-glucopyranoside (5a). A) 
Methyl -𝛽-O-glucopyranoside starting material. B) Glucopyranoside after 
conjugation to PBA followed by permethylation. 
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Figure 10: 13C NMR, DMSO-d6, Methyl 𝛽-D-glucopyranoside (5a). A) 
Methyl -𝛽-O-glucopyranoside starting material. B) Glucopyranoside after 
conjugation to PBA followed by permethylation  
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Figure 11: COSY and NOESY spectra for proton and methyl group 
assignment. A) COSY assignment of 1H peaks for product 1a. B) NOESY 
spectra indicating methylated hydroxyl groups on the 1, 2, and 3 carbons 
for Methyl 𝛽-D-glucopyranoside (5a). 
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2.4 Conclusion 
In conclusion, a one-pot method for derivatization and methylation of glycans with 
PBA under basic conditions has been demonstrated. Due to the unique specificity of PBA, 
a site-specific permethylation proceeds for gluco- galacto- and manno- pyranosides and 
PBA conjugation couples with permethylation results in unique profiles characterizable 
through basic NMR and mass spectroscopy techniques. PBA was shown to bind to each 
sugar in the following manner; methyl 𝛽-D-glucopyranoside at carbons 4 and 6, methyl 𝛽-
D-galactopyranoside at carbons 3 and 4, and lastly methyl α-D-mannopyranoside at 
carbons 2 and 3 (Figure 12). This research proposes both a novel and viable method for 
glycan analysis and shows both the regioselectivity of PBA under basic aqueous conditions 
and well as its stability during permethylation procedures.  
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Figure 12: 1H NMR comparison of methyl pyranoside products. 
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CHAPTER 3 
SYNTHESIS AND EVALUATION OF BORONIC ACID CONTAINING 
MACROMOLECULES AND LECTIN MIMETICS 
3.1 Introduction 
Carbohydrate recognition is a crucial event in many biological processes.1 For example, 
cell surface glycans, existing as glycoproteins, glycolipids or proteoglycans are involved 
in a variety of biological processes including cellular adhesion, cell signaling, cell-cell 
communication, and immune response.2-4 Cell surface glycans are highly associated with 
diseases development, such as inflammation and cancers.5,6 Over expression of cell surface 
glycan SAs is confirmed in cancer cells compared to normal control.7 Therefore, sensitive 
profiling of cell surface glycans is highly demanded for basic glycomic advancement, 
clinical diagnostics, and therapeutic applications. In fact, the large diversity and complexity 
of glycan structures together with their crucial role in many physiological or pathological 
processes require the development of new techniques for analyses. Lectins are 
carbohydrate-binding protein having at least one non-catalytic domain that binds reversibly 
to a specific carbohydrate.8 Due to their specificity, they have been largely employed to 
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identify cell surface glycans and glycoconjugates. Fluorescently labeled lectins have been 
widely used as intracellular and extracellular labels for cellular glycan profiling.9-11 
Further, lectin arrays using lectins as probes are well established to determine the specific 
glycan markers among different cell populations.12 In addition, lectins are also used for 
cellular targeting, showing promise in multiple applications including the targeting of 
apoptotic and autophagic pathways useful in anticancer therapies.13 Although natural 
lectins are very important tools for glycoscience research and application, they also have 
major limitations such as difficulty to produce, instability toward rigorous use, high cost 
and lack of availability.14  Another limiting factor is low binding affinity and specificity 
leading to poor sensitivity for analytical assays, because rarely is any glycan found at high 
abundance in a biological sample.15 In an effort to increase the binding specificity and 
affinity, clustered or linked lectins were explored as multivalency is typically regarded as 
one of the most important aspects in glycan-protein interactions.16,17 
Boronic acids react with 1,2 and 1,3 diols of saccharides in aqueous media through a 
reversible boronate ester formation.18-20 This interaction has been explored for potential 
application in analysis of glycans. So far, boronic acid containing ligands have been 
employed as artificial carbohydrate receptors,21 membrane transport agents,22 and cell 
surface carbohydrate recognition ligands.23 It has been reported that phenylboronic acid 
can selectively bind to the glycerol side chain of SAs under physiological conditions, and 
the complex is stabilized through coordination of the amide NH or CO located at the C-5 
position of SAs.24 This anomalous binding profile enables significantly increased binding 
efficiency of boronic acid to SAs in comparison to other sugars, which strongly suggests 
an innovative molecular targeting platform for selective recognition of cell surface SA 
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residues of both glycoproteins and glycolipids. Taking advantage of the specific and 
reversible binding of SAs residues to boronic acid in neutral pH, a potentiometric method 
employed a boronic acid-modified gold electrode was developed for cell surface SAs as 
well as free SAs.25 The detection method was based on the change in charge density of the 
electrode, due to the binding of SA residues. This method enabled a label-free, living cell 
operative, and real-time manner cytology, and was successfully applied to differentiate the 
degree of tumor metastasis through the detection of cell-membrane SAs.26 In this study, 
we designed protein-PBA conjugates as lectin mimetics. Specifically, bovine serum 
albumin (BSA)-PBA conjugates were synthesized in a density controlled manner by 
targeting both aspartic and glutamic acids to afford the lectin mimetics with multivalent 
PBA as multivalence is a key factor for glycan-protein binding of both specificity and 
affinity. The resultant BSA-PBA conjugates were characterized by SDS-PAGE, MALDI-
TOF MS. Further, its cell surface glycan binding capacity was confirmed by competitive 
lectin assay examined by flow cytometry. 
3.2 Materials and methods 
All solvents and reagents were purchased from commercial sources and were used as 
received, unless otherwise noted. Deionized water was used as a solvent in all procedures. 
PBA, ARS, BSA, EDC, MTT,  and maleimide functionalized silica beads, Sephadex G-25  
were purchased from Sigma-Aldrich (St. Louis, MO). Glc, Methyl -O-glucopyranoside, 
Gal, Methyl -O-galactopyranoside, Man, Methyl--O-mannopyranoside, SA, and Lac 
were purchased from Sigma-Aldrich (St. Louis, MO). MAA-FITC and SNA-FITC were 
purchased from Bio-World (Dublin, OH). 2--O-Methyl glycoside of Neu5Ac was 
synthesized as a literature method.27 
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3.2.1 BSA-PBA conjugation 
BSA (100 mg, 1.5 mol) and PBA (30 mg, 200 mol) were dissolved in 5 mL of 0.05 
M 2-(N-morpholino)ethane sulfonic acid buffer (MES; pH 6.0.). To this mixture, EDC (15 
mg, 80 M) was added at constant stirring and allowed to react overnight at room 
temperature. Then, the reaction mixture was subjected to Sephadex G-25 column with 
ddH2O as elute for purification and lyophilized. BSA-PBAs of different densities were 
prepared using same procedure as above by changing the ratios of BSA to PBA. 
Characterization was carried out by SDS-PAGE using both Coomassie blue and ARS as 
stains and imaged on a Typhoon 9410 Variable Mode Imager. 
3.2.2 Matrix-assisted laser desorption ionization/time-of-flight mass spectrometry 
The high purities and expected structures of the conjugated BSA-PBA derivatives were 
verified by MALDI-TOF MS using a Bruker Autoflex III MALDI-TOF mass spectrometer. 
The sample was applied onto the target plate using the dry droplet technique, in which 1 
µL sample containing 1µg total protein in 0.1% trifluoroacetic acid (TFA) was mixed with 
1 µL matrix (20 mg/mL sinappic acid in 0.1% TFA, 40% acetonitrile). The spots were 
dried at room temperature to allow sample crystallization prior to insertion into the 
instrument and the spectrum was obtained in linear mode.  
3.2.3 BSA-PBA immobilization 
BSA-PBA (45 mg, 2 mM) and maleimide functionalized silica beads (250 mg) were 
dissolved in phosphate buffered saline (PBS, 3 mL, 0.1 M, pH 7.4) and reacted for four 
hours at room temperature. The reaction mixture was then centrifuged and washed with 
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PBS three times to remove unreacted BSA-PBA. The same procedure was used for 
immobilization of all BSA-PBA conjugates as well as unmodified BSA. 
3.2.4 Alizarin Red S binding assay 
BSA-PBA modified silica beads (15 mg) were incubated with ARS (400 M) in PBS 
(1 mL, 0.1 M, pH 7.4) for 30 min at room temperature and centrifuged to remove unreacted 
ARS. The beads were then centrifuged and washed with 0.1 M PBS (pH 7.4)  three times 
to remove unreacted or loosely bound ARS followed by incubation of these silica beads 
with 100 mM sugar solutions (Glc, Methyl -O-glucopyranoside, Gal, Methyl -O-
galactopyranoside, Man, Methyl -O-mannopyranoside, Neu5Ac, 2--O-Methyl 
glycoside of Neu5Ac, and Lactose) in 0.1 M PBS (1 mL, pH 7.4) for 30 min at room 
temperature, respectively. Supernatant containing displaced ARS was removed after 
centrifugation and subjected to UV-vis spectroscopy. The absorbance of each well was 
measured on a microplate reader (Molecular Devices Spectrometer Plus 384) at 570 nm. 
3.2.5 Cell culture 
Raw 264.7 cells (ATCC) were cultured using DMEM supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptavidin at 37 °C in a humidified 5% CO2 
atmosphere. Subculture was performed when the cells had 80 - 90% confluence using 
trypsin-EDTA. 
3.2.6 MTT assay 
The biocompatibility of the BSA-PBA conjugates was measured by MTT assay. RAW 
264.7 cells were seeded in 96 well plates at a density of 0.5 x 104 cells/well in medium and 
incubated for 24 hours at 37 oC w/ 5% CO2. After 24 hours, the medium was removed and 
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new medium, supplemented with BSA-PBA conjugates, at varying concentrations (0.062, 
0.125, 0.25, 0.5 and 1 M). After an additional 24 hours, the cell medium was again 
removed and 100 L of 5 mg/mL MTT solution was added to each well, and the plates was 
incubated for 4 hours. The MTT solution was removed and 100 L of 100% DMSO per 
well was added to solubilize the precipitate and the plates were shaken for 10 min. The 
absorbance of each well was measured on a microplate reader at 570 nm. 
3.2.7 Flow cytometry 
Raw 264.7 cells were seeded at 4 x 105 cells/well (5 mL tubes) and treated with BSA-
PBA conjugates for 90 min. The cells were then washed 3 times with cold phosphate 
buffered saline (PBS; 0.2 mL, pH 7.4) and suspended in 50 μL PBS solution (pH 7.4)  
containing MAA-FITC (10 μg/mL) or SNA-FITC (10 μg/mL). After incubation for 30 min 
at room temperature, the cells were washed with cold PBS (pH 7.4) 3 times and 
resuspended in 500 μL of the same buffer for flow analysis. A minimum of 10,000 cells 
were measured each time. The fluorescence intensity of FITC-labeled lectins was 
subtracted from the intensity of the cell-lectin complex. All experiments were carried out 
in triplicate and spectra were obtained on a BD FACSCanto II Flow Cytometer. 
3.3 Results and discussion 
Considering PBA’s ability to reversibly bind 1,2 and 1,3 diols in aqueous media along 
with BSA’s well tolerated and widespread application, BSA-PBA conjugates were 
synthesized via EDC coupling. In this instance, amidation of carboxylic acids in BSA was 
followed by conjugation to amine moieties presented by PBA in the presence of EDC 
dissolved in MES buffer (Figure 13). Conjugation was followed by purification on Hi-Trap 
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Sephadex G-25 column by using H2O as eluent. Different densities of BSA-PBA 
conjugates were synthesized by altering the ratio of PBA to BSA.  
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Figure 13: Synthesis of BSA-PBA conjugates 
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3.3.1 SDS-PAGE characterization 
The resultant BSA-PBA conjugates were characterized by SDS-PAGE gel with 
Coomassie blue and ARS staining assay. First, BSA-PBA conjugates were characterized 
by SDS-PAGE, where the BSA-PBA conjugates showed an increase in molecular weight 
(Figure 14A). ARS binds to BA in a 1 to 1 ratio and a dramatic change in both color and 
fluorescent emissions can be monitored. Therefore, the BSA-PBA conjugates 
characterized on SDS-PAGE were stained with ARS. As shown in Fig. 1B, clear yellowish 
spots of all three BSA-PBA conjugates were observed, but not for unmodified BSA due to 
the lack of ARS binding. In the same respect, only bound ARS is fluorescent and can be 
seen in Figure 14C. This finding not only confirms binding of ARS to BA but also 
eliminates the possibility of non-specific binding. These data confirm that BSA-PBA 
conjugates were successfully synthesized. 
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Figure 14: SDS-PAGE Characterization of BSA-PBA conjugates. A) 
Coomassie Blue staining; B) ARS staining (C) Fluorescent image of SDS-
PAGE with ARS staining. M: Protein Molecular Weight Marker, BSA: 
Bovine Serum Albumin, 1: BSA-PBA1, 2: BSA-PBA2, 3: BSA-PBA3.  
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3.3.2 MALDI-TOF analysis 
MALDI-TOF MS was used to characterize the BSA-PBA conjugates using a sinapic 
acid matrix with a Bruker Autoflex III mass spectrometer. The mass spectrum acquired for 
unmodified BSA showed the typical profile of a non-glycosylated, non-functionalized 
protein. The molecular ion peak was broadly dispersed over 66,430 Daltons due to an 
isotopic effect relative to the size of the protein (Figure 15A). The m/z ratio increases and 
peak position shifts to the right as BSA functionalized with PBA and the amount of shift 
is directly correlated to the amount of PBA conjugated to BSA (Figure 15A (2, 3, 4)). As 
a result, three BSA-PBA conjugates were obtained with the PBA/BSA ratio increase in the 
reactions, affording BSA-PBA1 determined to have 5 PBA functionalities, BSA-PBA2 to 
have 10 PBA and BSA-PBA3 to have 15 PBA functionalities. The MALDI-TOF MS 
spectrum of BSA (1) and BSA mixed with PBA in different ratios but without EDC (Figure 
15B (2-4)) showed no molecular weight change, indicating no PBA conjugation occurred.  
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Figure 15: Characterization of BSA-PBA conjugates by MALDI-TOF MS. 
A) MALDI-TOF MS spectrum of BSA (1), BSA-PBA1 (2), BSA-PBA2 (3) 
and BSA-PBA3 (4) obtained in different ratios of BA in the presence of 
EDC; B) MALDI-TOF MS spectrum of BSA (1) and BSA (2-4) mixtures. 
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3.3.3 Glycan binding 
The carbohydrate binding capacity of BSA-PBA conjugates was examined by ARS 
displacement assay, which has been used extensively to quantify boronic acid and 
carbohydrate binding capabilities.28-30 Briefly, ARS shows a color change from red to 
yellow when bound to BSA-PBA and shifts the UV absorption wavelength from 520 to 
460 nm in PBS (pH 7.4). When adding a (0.1 M) fructose, the fructose-boronic acid 
complex forms, releasing ARS with the color changing from yellow back to red and the 
wavelength shifting back to 520 nm (Figure 16B).  
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Figure 16: ARS displacement assay in PBS (pH 7.4) buffer. A) ARS 
solutions after incubation with PBA and BSA-PBA conjugates then 
fructose: (1) ARS, (2) ARS mixed with free PBA, (3) ARS mixed with free 
PBA, then with fructose, (4) ARS mixed with free BSA, (5) ARS mixed 
with BSA-PBA, (6) ARS mixed with BSA, then with fructose, (7) BSA. B) 
US spectra of ARS solutions after incubation with PBA or BSA-PBA 
conjugates then fructose: (1) ARS, (2) ARS mixed with free PBA, (3) ARS 
mixed with free PBA, then with fructose, (4) ARS mixed with free BSA, 
(5) ARS mixed with BSA-PBA, (6) ARS mixed with BSA-PBA, then with 
fructose, (7) BSA. 
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3.3.4 Glycan specificity 
Silica beads have been widely used as small, rigid particles for high performance 
affinity chromatography as and is capable of withstanding high flow rates and/or pressures. 
Recently, surface functionalized silica beads have received wide spread attention for 
affinity chromatography applications.31,32 In the present study, BSA-PBA conjugates were 
immobilized onto silica beads and their respective carbohydrate binding affinity and 
specificity were investigated. First, BSA-PBA was dissolved in PBS (pH 7.4). This BSA-
PBA solution was added to commercially available maleimide functionalized silica beads 
and allowed to thiol- maleimide coupling react for 4 hours at room temperature. Then, the 
unreacted BSA-PBA was removed by washing the silica beads with PBS (pH 7.4) 3 times 
to afford the BSA-PBA functionalized silica beads (SB-BSA-PBA). Then, the resultant 
SB-BSA-PBA was characterized by ARS binding assays comparing to BSA modified silica 
beads and un-treated maleimide functionalized silica beads as well. As a result, SB-BSA-
PBA incubated with ARS solution showed strong ARS binding compared to unmodified 
silica beads and BSA modified silica beads incubated with the same ARS solution (Data 
not shown). 
Next, the SB-BSA-PBA was used to evaluate the carbohydrate binding affinity and 
specificity by ARS displacement assay. First, SB-BSA-PBA (15 mg) was incubated with 
ARS (0.1 M) in PBS (pH 7.4) at room temperature for 30 min. After centrifugation, the 
supernatant containing unreacted ARS was removed by pipet and the silica beads were 
washed three times with PBS (pH 7.4). Among the BSA-PBA conjugates used, the BSA-
PBA3 modified silica beads displayed the highest binding of ARS as it has higher density 
of PBA compared to BSA-PBA1 and BSA-PBA2 (Figure 17). The BSA modified silica 
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beads and silica gel beads alone showed no ARS released and were subtracted as controls 
during the experiment. To support this evidence, ARS displacement by the introduction of 
a high concentration (0.1 M) of saccharides was investigated. This method has been used 
in the past to determine multiple facets of PBA binding to include saccharide kinetics, 
affinity, and specificity.33 The ARS bound SB-BSA-PBA was incubated with free 
monosaccharides and their O-methyl glycosides solution (0.1 M) in PBS (pH 7.4) at room 
temperature for 30 min to displace the bound ARS from the SB-BSA-PBA. O-methyl 
glycosides of all mimic native form of sugars in glycan chains linked via O-glycosylation. 
The displaced ARS was subjected to UV-vis spectroscopy, and the corresponding 
absorbance data was in direct correlation with the amount of ARS released from the SB-
BSA-PBA, which is the indicator of the binding affinity and specificity of BSA-PBA 
conjugates to free monosaccharides and their O-methyl glycosides. As a result, BSA-PBA3 
conjugates with the highest density of PBA showed highest binding capacity for both free 
monosaccharides and their O-methyl glycosides compared to BSA-PBA1 and BSA-PBA2 
modified silica beads (Figure 17). However, there was no significant difference was 
observed regarding specificity for both monosaccharides and their O-methyl glycosides. 
This result indicates that the SB-BSA-PBA binding is dependent on the number of PBAs 
but it is unknown based on this assay if the saccharide truly makes a difference.  
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Figure 17: Carbohydrate binding capacity of BSA-PBA. 
ARS displacement assay immobilized on silica gel beads: BSA-PBA 
conjugates were immobilized onto maleimide-functionalized silica gel, 
incubated with ARS, followed by washing and incubation with 
monosaccharides and their methyl glycoside. Absorbance at 520 nm was 
recorded for the free ARS replaced by sugars from the beads (Sialic acid: 
N-acetylneuraminic acid, Sialoside: 2-O-Methyl-α-D-N-acetylneuraminic 
acid). 
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3.3.5 Biocompatibility 
The relative cytotoxicity of BSA-PBA conjugates towards Raw 264.7 cells were 
estimated by an MTT viability assay. Briefly, Raw 264.7 cells were seeded into 96-well 
plates with at 1 x 104 density per well in 200 μL of medium. After 24 h of incubation, the 
culture medium was removed and replaced with 200 μL of some medium containing serial 
dilutions of BSA-PBA conjugates. The cells were grown for another 24 h. Then, 200 μL of 
0.5 mg/mL MTT assays stock solution, in phenol red free medium, was added to each well. 
After incubating the cells for 4 h, the medium having unreacted dye was removed carefully. 
The obtained purple formazan crystals were dissolved in 100 μL per well SDS-HCl and the 
absorbance was measured at 570 nm. As a result, no apparent cytotoxicity to Raw 264.7 
cells was observed up to a concentration of 1 M for all three BSA-PBA conjugates. 
Instead, an increased level of cell proliferation was observed for higher concentrations of 
the three BSA-PBA conjugates (Figure 18). 
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Figure 18: MTT assay to assess cell viability.  
Raw 264.7 cells were incubated with BSA, PBA, and BSA-PBA conjugates 
for 24 h at 37 oC. The error bars represent one standard deviation of the 
averages cell percent viability (n=3). 
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3.3.6 Cell surface targeting 
SAs are found linked to Gal residues on the cell surface by either α-2,3 or α-2,6 
linkages.34 In this study, the binding capacity of BSA-PBA conjugates to cell surface SA 
was determined via competitive inhibition of the binding of lectins that specifically 
recognize SA by flow cytometry analysis (Figure 19). First, Raw 264.7 cells  were 
incubated with BSA-PBA conjugates for 90 minutes, followed by incubation with MAA-
FITC and SNA-FITC, which specifically bind to α-2,3 and α-2,6 linked SAs, 
respectively.35 From the flow cytometry study, MAA-FITC showed very strong binding 
compared to SNA-FITC on the cell surface of Raw 264.7 cells cultured under the normal 
condition. And, it was apparent that BSA-PBA could inhibit binding of MAA-FITC by 
blocking available binding sites with respect to the number of PBA residues available from 
BSA-PBA for interaction. SNA-FITC on the other hand showed a drastic decrease in 
binding when incubated with BSA-PBA1 cells followed by an increase in fluorescent 
intensity with BSA-PBA2 and BSA-PBA3, which have high PBA content. This inverse 
relationship may be due to PBA location is different in these three BSA-PBA conjugates 
and its ability to bind cell surface glycans may different, thereby having different inhibition 
capacity for SNA binding. It is also possible that BSA-PBA2 and BSA-PBA3 may induce 
more expression of α-2,6 linked SAs, resulting in an increase in the fluorescent intensity 
of the SNA-FITC. We plan to quantify cell surface expression of Mϕ upon incubation with 
these lectin mimetics in our future immunomodulation study in detail. To explain the 
reduction in fluorescent intensity caused by the BSA control, it is possible the BSA may 
limit this effect showing true 100% lectin binding. 
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Figure 19: Cell surface SA binding capacity of BSA-PBA lectin mimetics. 
Raw 264.7 cells were incubated with BSA, BSA-PBA conjugate (5 μg/mL), 
followed with MAA and SNA lectin (10μg/mL) respectively. The error bars 
indicate one standard deviation of the averaged fluorescent intensity (n=3). 
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3.4 Conclusion 
BSA-PBA conjugates were successfully synthesized and evaluated as lectin mimetics 
for glycan recognition has been demonstrated. The conjugates were synthesized in a 
density controlled manner using traditional EDC coupling techniques affording amide 
derivatives from carboxylic acid residues within the BSA protein structure. The BSA-PBA 
conjugates were immobilized onto maleimide functionalized silica gel via thiol–maleimide 
interactions and used to study the sugar binding specificity of several sugars by ARS 
displacement assay. Evaluation of biocompatibility using an MTT assay showed no effect 
on cell viability after 24 hours. Lastly, cellular studies confirm binding of BSA-PBA 
conjugates to Raw 264.7 cells cell surface SA based on the inhibition of lectin-FITC 
binding. These lectin mimetics have more favorable properties compared to natural lectin 
in terms of toxicity and inherent immunogenicity and will provide an important tool for 
future glycomics, biosensor and immunomodulation research and applications.  
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CHAPTER 4 
SYNTHESIS AND EVALUATION OF GLYCOPOLYMERS AS BIOMIMETIC 
GLYCOLIGANDS FOR MACROPHAGES TARGETING 
4.1 Introduction 
Mϕ cells play significant roles in immune system responses.1 They are the first cells to 
recognize and engulf foreign substances (antigens), breaking them down and presenting 
the smaller proteins to T-lymphocytes, functioning as antigen presenting cells. Mϕs also 
express cytokines to help regulate the activity of lymphocytes and are differentially 
activated into different functional subtypes in response to antigen stimuli or cytokines 
present in the microenvironment.2 They differentiate, or polarize, into classically (M1) or 
alternatively (M2) activated cells, both representing phenotypic extremes of Mϕ 
differentiation.3,4 In particular, control of Mϕ phenotypic balance from proinflammatory 
M1 to reparative M2 is a choice of investigators to optimize the host response. Therefore, 
modulating Mϕs offers an opportunity to augment or inhibit specific immune functions and 
thus contribute to the discovery of novel therapeutic applications. 
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Mϕs express various lectins as receptors for modulating specific immune responses.5,6 
In particular, two major classes of lectins in innate immunity are promising targets: (i) C-
type lectin receptors (CLRs), which are calcium-dependent carbohydrate binding receptors 
and (ii) SA binding Ig-like lectins (Siglecs), which are mainly expressed by immune cells. 
CLR receptors recognize carbohydrate moieties present on pathogens, but also bind to 
altered carbohydrate structures found on apoptotic, cancerous, and necrotic cells.5, 7,8 Man 
receptor (Cluster of Differentiation 206, CD206) and DC-SIGN (Dendritic Cell-Specific 
Intercellular adhesion molecule-3-Grabbing Non-integrin) also known as CD209 are CLRs 
widely expressed on the surface of Mϕs and both recognize and bind to Man type 
carbohydrates commonly found on viruses, bacteria, and fungi. This binding interaction 
activates phagocytosis.9,10 On the other hand, Siglecs recognize SAs as ligands and are 
expressed on human leukocytes in a cell-type restricted manner that regulates cellular 
adhesion, antigen uptake and signaling.11,12 Siglec-1’s (CD169) specific expression, makes 
it an attractive target for delivering antigens to tissue Mϕs via Siglec-1-mediated 
endocytosis.13,14 Siglec-7 is expressed on Mϕs as well and based on its restricted 
expression, it has been proposed as an attractive target for cell-targeted therapies directed 
towards myeloid cells.11, 15 Therefore, glycan binding by CLRs and Siglecs can be 
exploited for immunotherapy and the design of glycan-based therapeutics will inspire new 
biotechnological approaches to effectively tune immunological processes in cancer and 
infectious disease.16-18 
Glycans are often presented in a multivalent fashion on either pathogens or repetitive 
protein sequences expressed on the cell surface and their interactions with receptors 
depends on multivalent recognition events.19 In addition, CLRs and Siglecs show 
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multimerized expression on the cell surface. Therefore, to create the ultimate targeting 
ligand, a high affinity glycan must be combined with highly multivalent presentation.20 In 
this regard, glycopolymers, typically polymers with glycan pendant groups, have been 
extensively explored as multivalent carbohydrates for probing carbohydrate-protein 
interactions in an effort to gain a better understanding of their underlying mechanisms.21 
For example, glycopolymers can act as agonists or antagonists for understanding the 
molecular mechanisms of many biological processes, and also provide tremendous 
opportunities for therapeutic applications. Therefore, glycopolymers may serve as active 
glycoligands for targeting Mϕs to initiate specific immune responses.22 The precise design 
of synthetic glycopolymers has vital importance when it comes to mimicking the chemical 
and biological functions of glycoconjugates, as well as providing enhanced biological 
activities. Design and synthesis of glycopolymers has become a very important research 
field, where significant efforts are highly needed to develop advanced glyco-polymeric 
architectures with improved performance.23  
The precision in the design of synthetic glycopolymers, including chain composition, 
monomer sequence and architecture, has vital importance in mimicking the chemical and 
biological functions of glycoproteins.24 In addition, the glycan attachment to the polymer 
backbone is essential for its performance but has been paid little attention until now. So 
far, most glycans were attached to the polymer backbone through O-linked spacers or N-
reductive amination-linked spacers, however, neither is a native glycan-amino acid linkage 
on glycoproteins, which may be a reason for the lower performance of glycopolymers.25 
The N-glycans are mostly found in natural glycoproteins, where the sugar molecule is 
attached to a nitrogen atom of an Asn residue in a protein. Previously, a straightforward 
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synthesis of N-glycan polymers for the development of high-affinity and selective ligands 
was developed.25 In this study, N-sialylglycan polymers that closely mimic the natural N-
sialylglycan polymers were proposed for targeting Mϕs Siglecs. 
A micropillar/microwell chip platform facilitating miniaturized three-dimensional (3D) 
cell cultures and high-throughput biochemical and cell-based assays has been developed.26 
In this study, the immunomodulation effect of the N-sialylglycan polymers on mouse Mϕ 
RAW 264.7 cells on the micropillar/microwell chip platform was investigated. 
Specifically, an assay was established on the micropillar/microwell chip platform chip to 
streamline the evaluation of dose-dependent cytotoxicity and cell activation 
simultaneously, which allows one to examine the expression level of cell surface markers 
and the cytokine secretion profiles on 3D-cultured Mϕs in a high-throughput fashion. The 
micropillar chip coupled with the microwell chip can be used to investigate immune cell 
responses to external stimuli, cell staining, and imaging, thus allowing multiplexed, 
miniaturized, 3D immune cell-based assays in high throughput fashion alternative to 
conventional in vitro glycoarrays and multi-well plate platforms 
4.2 Methods and materials 
All solvents and reagents were purchases from commercial sources and were used as 
received. Lactose (Lac) was purchased from Sigma (USA). CMP-Neu5Ac was purchased 
from Nacalai Tesque, Inc. (Kyoto, Japan). 2,3-Sialyltransferase, 2,6-silayltransferase 
were granted by Prof. Peng George Wang at Georgia State University. Deionized water 
with a resistance of 18M cm-1 was used as a solvent in all polymerization reactions and 
dialysis experiments. Dialysis was performed with cellulose membranes with a molecular 
weight cutoff of 3kDa with water as solvent. 1H and 13C NMR spectra were measures at 
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room temperature with a Bruker AV400 MHz spectrometer and D2O or CD3OD was used 
as deuterated solvent. 
4.2.1 Synthesis and characterization of N-glycan polymers 
Synthesis of glycosylamines via Likhosherstov method (Scheme 3): The preparation 
of glycopolymers began with synthesis of glycosylamines prior to polymerization. A 
solution of Lac (5.0 mmol) and ammonium bicarbonate (395.0 mg, 5.0 mmol) in 20 mL of 
aqueous ammonia was kept in an oil bath at 42 C for 40 h and then was freeze-dried. The 
dried product was directly subjected to the next reaction without purification.  
Acrylation: After amination, the dry lactosylamine (2) was dissolved in 60 mL of 
CH3OH-H2O (1:1, V/V) and 3.0 g of Na2CO3 was added. The mixture was cooled in an ice 
bath for 30 min and then a solution of 1.28 mL of acryloyl chloride in 7 mL of THF was 
added dropwise. After that, the reaction mixture was stirred at 0 oC for another 1 hour. The 
organic solvents were evaporated under reduced pressure and the remaining aqueous layer 
was lyophilized to dryness.  
N-(Prop-2-enoyl)--D-lactosylamine: Glycomonomer (3) was purified by silica gel 
column chromatography eluted with CHCl3-CH3OH (70: 30). 1H NMR (D2O, 400 MHz) 
δ: 6.30 (1H, d, 4.4), 6.29 (1H, d, 6.8), 5.85 (1H, dd, 6.8, 4.4), 5.05 (1H, d, 9.2), 4.44 (1H, 
d, 8.0), 3.42-3.91 (12H, m); 13C NMR (D2O, 100 MHz) δ: 169.4, 129.5, 129.4, 102.9, 79.3, 
77.9, 76.5, 75.4, 75.1, 72.6, 71.6, 71.0, 68.6, 61.1, 60.0. 
Synthesis of N-lactosyl glycopolymer (4) (Scheme 2): 4-Chloroaniline (4.34 mg, 
0.034 mmol) and sodium nitrite (NaNO2, 2.82 mg, 0.04 mmol) were dissolved in 1.2 mL 
of H2O-THF (1: 1) in a three-necked flask. The mixture solution was cooled in an ice bath 
for 30 min and then 12 µL of HBF4 solution (48 wt%, 0.092 mmol) was added to react for 
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1 hour. Then, a degassed mixture of N-(prop-2-enoyl)--D-lactospyranosylamine (3, 134.7 
mg, 0.34 mmol), acrylamide (96.6 mg, 1.36 mmol) and NaOCN (3.0 mg, 0.046 mmol) 
dissolved in 0.8 mL of H2O was added into the flask containing the diazonium salt. The 
reaction solution was kept in an oil bath to react for 20 hours at 60 C. The resultant mixture 
was dialyzed against deionized water for 2 days to remove the impurity and then freeze-
dried to yield glycopolymer (143.1 mg, 61.9%). The molecular weight was about 13284.2 
as determined by 1H NMR spectrum. 
Enzymatic synthesis of sialyllactose N-glycan polymer (5, 6) (Scheme 5): Lactosyl 
glycopolymer (4, 10.0 mg, 0.75 µmol) and CMP-Neu5Ac (3.6 mg, 5.66 µmol) were 
dissolved in 800 µL of Trix-HCl buffer (pH 8.35). To the mixture solution was added 1.0 
U α2,6-sialyltransferase and the mixture solution was kept in a water bath to react for 17 
hours at 37 C. The resultant α2,6-sialylloctose glycopolymer (5) was purified by dialysis 
against deionized water for 2 days. The same protocol was applied to synthesize and purify 
the α2,3-sialylloctose glycopolymer (6). The resultant sialyllactose glycopolymers were 
characterized by 1H NMR spectra. 
Characterization of sialyllactosyl glycopolymer: The resultant sialylglycopolymers 
were characterized by 1H NMR spectra as well (Figure 20). The successful sialyation of N-
Lac copolymer (4) was confirmed by the signals of protons from Neu5Ac (1.95 ppm, CH3-
Neu5NAc and 2.68 ppm, H3eq-Neu5Ac), the degree of sialyation and the polymer length 
as well were calculated also using the 1H NMR spectra by comparing the integration value 
of proton signals from aromatic protons (7.31 ppm and 7.16 ppm), anomeric protons (4.98 
ppm and 4.40 ppm) of Gal and Glc, C3-equatorial proton (2.70 pm) of Neu5Ac and methyl 
and methylene protons of polymer backbone. As a result, more than 90% enzymatic 
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sialylation was obtained for both 2,3-sialylation and 2,6-sialylation of N-Lac copolymer 
(Figure 20, C,D). 
4.2.3 Biocompatibility 
Dose-dependent cytotoxicity of the glycopolymers against 3D-cultured RAW 264.7 
cells was evaluated on the micropillar/microwell chip platform. Briefly, the micropillar 
chip containing 60 nL of RAW 264.7 cells was sandwiched with the microwell chip 
containing 950 nL of synthetic glycopolymers, including N-lactosyl polymer, N-α2,3-
sialolactosyl polymer, and N-α2,6-sialolactosyl polymer, at a concentration range of 0, 10, 
50, 250, 1250, and 6250 µg/mL (dissolved in DMEM) for 24 hours, then rinsed with 0.9% 
saline solution, and stained with calcein AM and ethidium homodimer-1 for 1 hour. 
Fluorescent cell images were acquired from the chip using the S+ scanner, and dosage 
response curves were obtained. 
4.2.4 Cell surface targeting 
Next, the immune response to RAW 264.7 cells was examined on the chip platform. 
The micropillar chip containing 3D-cultured RAW 264.7 cells (60 nL) was sandwiched 
with the microwell chip containing 950 nL of 1250 µg/mL glycopolymer and incubated at 
37°C and 5% CO2 for 24 hrs. The treated cells were rinsed with Tris-buffered saline (TBS) 
twice for 10 min each and fixed in a mixture of ice-cold methanol and acetone (at 1:1 ratio) 
for 10 min at room temperature. After rinsing with TBS, cells were incubated with blocking 
buffer for 1 hour at room temperature, and stained with 0.01 mg/mL of the FITC-labelled 
primary antibodies (rat anti-mouse CD40, CD1d, CD80, and I-Ad) at 4°C overnight. 
Finally, the cells were stained with 1 µg/mL DAPI for 30 min, and rinsed with TBS twice 
for 10 min each. After drying the micropillar chips for at least 3 hours in the dark, 
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fluorescent images were acquired from the chip using the S+ scanner for fluorescent 
extraction and data analysis to detect the changes of cell surface biomarkers. 
4.3 Results and discussion 
In this study, N-lactosyl glycopolymer was synthesized from free glycan via 
glycosylamine intermediates followed by acrylation and polymerization via cyanoxyl-
mediated free radical polymerization (CMFRP). The synthetic method is facile with no 
protection and deprotection used in either glycomonomer or glycopolymer synthesis. Then, 
N-α2,3-sialolactosyl glycopolymer and N-α2,6-sialolactosyl glycopolymer were 
synthesized via enzymatic reaction with sialyltransferase. The enzymatic glycosylation 
was reported as a highly efficient synthesis method with nearly 100% product yield. 
Finally, cytotoxicity and Mϕ targeting effect of the N-glycan polymers on RAW 264.7 cells 
were investigated. 
4.3.1 Synthesis of N-(Prop-2-enoyl)--D-lactosylamine (3) 
A practical protocol for the selective amination of unprotected sugar derivatives was 
introduced by Likhosherstov et al., which used ammonium carbamate in methanol.27  In 
this method, with ammonium carbamate, the carbamic acid salt of glycosylamine formed 
as a white precipitate from the reaction solution, which allows easy purification from a 
crude carbohydrate preparation. In addition, carbamic salt formation prevents hydrolysis 
and glycosylamine-dimer formation. After obtaining the glycosylamine salt from free 
sugars, the N-acryloyl group was introduced by adding acryloyl chloride to the 
glycosylamine salts in methanol-water and in the presence of Na2CO3 at 0 oC, followed by 
the removal of excess acryloyl chloride and sodium carbonate to yield N-acryloyl-
lactosylamine as glycomonomers for N-glycan polymers synthesis (Scheme 3).  
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Scheme 3: Facile syntheses of glycosylamines. Likhosherstov method, and 
N-acryloyl derivatives as glycomonomers. 
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4.3.2 Synthesis of N-lactosyl glycopolymer (4) 
CMFRP is a straightforward approach for synthesizing glycopolymers in high yield 
with low polydispersity (PDI < 1.5). Polymerization can be conducted in aqueous solution 
and is tolerant of a broad range of functional groups excluding protection and deprotection 
steps often used in other methods. N-lactosyl glycopolymer (4) was synthesized via 
CMFRP in one-pot fashion (Scheme 4), in which, 4-chloroanaline was used as initiator for 
the copolymerization of N-acryloyl-lactosylamine and acrylamide. Initially, cyanoxyl 
radicals were generated by an electron-transfer reaction between cyanate anions from a 
sodium cyanate aqueous solution and aryl-diazonium salts prepared in situ through a 
diazotization reaction of arylamine in water. In addition to cyanoxyl persistent radicals, 
aryl-type active radicals were simultaneously produced, and only the latter species was 
capable of initiating chain growth. 
  
  110 
 
Scheme 4: Synthesis of N-glycan glycopolymer via CMFRP. 
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4.3.3 Syntheses of N-sialylglycan polymers 
The enzymatic glycosylation was reported as an efficient synthesis of oligosaccharides, 
without protection and in high anomeric control. In the past decade, enzymatic sialylation 
was explored to synthesize various sialyloligosaccharides, in which the glycosidic linkage 
between the SA and the acceptor carbohydrate is extremely controlled by the type of 
sialyltransferase selected. In the present study, the transfer of SA residue from CMP-
Neu5Ac to 3- and 6-positions of terminal Gal of N-Lac copolymer (4), by enzymes α2,3-
sialyltransferase and α2,6-sialyltransferase, were investigated to afford sialyllactose-
containing N-glycopolymer α2,6 Sialylglycopolymer (SGP) (5) and α2,3 SGP (6), 
respectively (Scheme 5). The polymers were characterized NMR spectra by comparing the 
integration value of proton signals allowing a determination as to the degree of sialyation 
and the polymer length (Figure 20). 
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Scheme 5: Enzymatic synthesis of sialyl N-glycan glycopolymers from N-
Lac glycopolymer. 
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Figure 20: NMR spectra of lactosylamines and glycopolymer derivatives. 
A) 1H NMR spectrum of N-(prop-2-enoyl)-B-D-lactopyranosylamine in 
D2O. B) 1H NMR spectrum of lactosyl glycopolymer in D2O. (C) 
1H NMR 
spectrum of 2,6-sialyllactose glycopolymer in D2O. (D) 
1H NMR 
spectrum of 2,3-sialyllactose glycopolymer in D2O. 
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4.3.2 Biocompatibility 
As a result of cytotoxicity assays, all N-glycan polymers were shown to be non-
cytotoxic against 3D-cultured RAW 264.7 cell at a concentration of 1,250 mg/mL except 
for N-α2,3-sialolactosyl polymer (4), which was cytotoxic at 1250 µg/mL (Figure 21). 
Therefore, further evaluations of immune cell modulation with glycopolymers were 
performed at 1250 µg/mL. 
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Figure 21: Cytotoxicity of N-glycan polymers against 3D-cultured RAW 264.7 
cells.Dose-dependent cytotoxicity of N-α2,3-sialolactosyl polymer (A) and N-
α2,6-sialolactosyl polymer (B) against RAW 264.7 cells have been 
demonstrated. The compounds were incubated with the cells for 24 hours on 
the chip. Green dots represent live RAW 264.7 cell spheroids stained with 1 
µM calcein AM and 1 µM ethidium homodimer-1. 
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4.3.3 Cell surface targeting 
Cell surface biomarker changes including CD40, CD1d, CD80, and IAd (major 
histocompatibility complex, MHC) were measured via immunofluorescent assay. These 
biomarkers have been studied extensively and used as a model for immunomodulatory 
effects as well as cell differentiation. Each of these biomarkers is located on various types 
of antigen presenting cells and their levels of expression are highly impactful on the 
immune response. Typically, upregulation of these unique receptors increases the cell’s 
level of activation, leading to an increased immune response. By monitoring their levels of 
expression, we can observe their level of activation and identify GM compounds that 
induce a desired effect as well as clarify our understanding of carbohydrate involvement in 
the cell defense. 
Next, cell surface binding of glycopolymers with RAW 264.7 cells was examined by 
measuring surface biomarker changes. As a result, CD40, CD80, CD1d, and MHC II were 
induced mostly with the N-sialyllactosyl polymers (4 and 5) (Figure 22) as compared to 
DMEM and LPS as negative and positive controls. In particular, N-α2,3-sialolactosyl 
polymer (4) showed the strongest induction of all four cell surface markers, indicating 
increased Mϕ modulation activity. This is correlated well with precedent reports that Mϕ 
receptors have a preference to binding glycan ligands with the Neu5Acα2-3Galβ1 
sequence.28 In addition, N-α2,6-sialolactosyl polymer (5) showed strong activity for 
inducing MHC II cell surface marker expression. 
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Figure 22: Expression of cell surface markers after treatment with 
glycopolymers. 
Fluorescent intensity of CD40, CD80, CD1d, and Class II MHC. The 
numbers indicate as follows: (1) for growth medium control, (2) for LPS, 
(3) for N-lactosyl polymer, (4) for N-α2,3-sialolactosyl polymer, and (5) for 
N-α2,6-sialolactosyl polymer, all 3D-cultured RAW 264.7 cells on the 
micropillar chip. (* for p < 0.05, ** for p < 0.01, and *** for p < 0.001). 
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5.1 Conclusion 
SA-terminated oligosaccharides expressed on the cell surface are involved in multiple 
types of cellular communication, cell adhesion and other signaling pathways. Therefore, 
synthetic SA-containing oligosaccharides may serve as biomimetic agents to help 
understand the underlying mechanisms of signaling such as in immunomodulation. A 
straightforward synthesis of N-glycan polymers via acryloyl-glycosylamine and direct 
polymerization from free saccharides, all in aqueous conditions, without 
protection/deprotection steps has been demonstrated. The present simple and efficient 
synthetic method can be applied to synthesize glycomonomers and glycopolymers from 
any free saccharide, either purified natural N-linked and O-linked oligosaccharides or 
synthetic N-linked and O-linked oligosaccharides, for a variety applications.  
The cytotoxicity and immunomodulation effect of novel biomimetic N-sialylglycan 
polymers was tested for cytotoxicity and immunomodulation activity on the chip platform 
in high throughput fashion. The N-sialylglycan polymers had a significant 
immunomodulatory effect on 3D-cultured RAW 264.7 cells. The N-α2,3-sialolactosyl 
polymer was non-cytotoxic to RAW 264.7 cell at a concentration of 1,250 mg/mL, while 
N-α2,6-sialolactosyl polymer showed toxicity at 1250 µg/mL. In addition, N-α2,3-
sialolactosyl polymer (4) showed stronger activity for inducing CD40, CD80, CD1d, and 
MHC II cell surface markers expression, indicating a high Mϕ modulation activity.   
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CHAPTER 5 
 
SUMMARY 
The major contributions of the work in this dissertation were the successful synthesis 
of a both boronic acid derived lectin mimetics as well as glycopolymers as GMs. One of 
the biggest challenges in designing carbohydrate sensors is the construction of the three-
dimensional framework to obtain the desired affinity and specificity toward a given glycan. 
Using polymers, dendrimers, proteins, and other larger molecules has afforded not only an 
increase in multivalency but also provides functional groups for complementary 
interactions. In addition, using these types of molecules also provides an opportunity to 
perform combinatorial chemistry without the need for extraneous planning and design of a 
limited number of materials.  
First, traditional approaches for studying cell surface glycans often employ the use of 
lectins, which recognize glycans with high specificity. However, the application of lectins 
is limited to their isolation from nature and limited number in comparison to glycan 
combinations. For this reason, BSA-PBA conjugates were synthesized in a density 
controlled manner by targeting both aspartic and glutamic acids to afford the lectin 
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mimetics with multivalent PBAs as multivalency is a key factor for glycan-recognition in 
both specificity and affinity. The resultant BSA-PBA conjugates were characterized by 
SDS-PAGE and MALDI-TOF MS. Mϕ cell surface glycan binding capacity was 
characterized by a competitive lectin assay examined by flow cytometry and an MTT assay 
showed biocompatibility. These novel lectin mimetics have the potential to find 
widespread use in both therapeutic and diagnostic applications as they can be wittingly 
modified, altering specificity and capacity. 
Glycopolymers as GMs were synthesized to work opposite that of the lectin mimetics 
in that they were to be bound by cell surface receptors rather than binding to cell surface 
carbohydrates. A straightforward synthesis of N-glycan polymers from free glycans via 
glycosylamine intermediates followed by acrylation and polymerization via CMFRP in 
one-pot fashion. No protection and deprotection techniques were used in either 
glycomonomer or glycopolymer synthesis. A typical synthetic procedure for N-glycan 
polymers from free monosaccharide and disaccharide, Glc, Gal, Man, GlcNAc and Lac, 
was demonstrated. In addition, enzymatic sialylation of the Lac-containing N-glycan 
polymers and their immunomodulation effects on RAW 264.7 cells were investigated by 
microchip/microwell cytokine assay. 
In summary, the work accomplished was a systematic preliminary study of the ability 
of lectin-mimetics and GMs ability to interact with RAW 264.7 cells. BSA-PBA 
conjugates were seen to bind to terminal SA residues based on flow cytometry and GMs 
were shown to elicit specific cellular response based on the polymer structure. Further 
investigation into immunomodulatory effects may require more effort concerning cytokine 
assay development. Also, more derivatives with varying functional group density as well 
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as orientation could be used to elicit different and even unique responses while helping to 
understand underlying mechanisms for specificity and affinity. 
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CHAPTER 6 
FUTURE PERSPECTIVE 
The Mϕ cell surface expresses a dense layer of glycans often terminated with SAs.1 
Due to their terminal position and properties, SAs are involved in the modulation of 
immune responses of Mϕs such as host-pathogen recognition, migration, and antigen 
presentation among other non-immune related processes. For example, a family of > 15 SA 
binding immunoglobulin superfamily lectins or Siglecs are expressed on a variety of cell 
types, but mainly on immune cells.2 Siglecs are cell surface transmembrane proteins 
thought to regulate immune responses via intracellular signaling domains. They bind SAs 
in various contexts and, depending on the Siglec and the interacting partner, can suppress 
or promote cellular activation, inflammation or apoptosis.3 Thus, targeting Mϕ cell surface 
glycans with lectins have great potential for modulating Mϕs to engineer immune responses 
toward a desired outcome, such as anticancer immunotherapy. However, a disadvantage of 
using natural lectins in immunotherapy is their inherent toxicity and immunogenicity.4 
Lectin mimetics like BSA-PBA conjugates may solve this problem. In this dissertation, the 
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Mϕ cell surface SA binding capacity of newly synthesized BSA-PBA conjugates were 
investigated by competitive lectin binding assays examined by flow cytometry and their 
biocompatibility with RAW 264.7 cells was investigated using an MTT assay. Further, their 
immunomodulation activity should be examined by quantifying cytokine release upon 
treating Raw 264.7 cells with BSA-PBA conjugates. These novel lectin mimetics are 
expected to find a wide range of applications in glycomics and biomedical research and 
development applications. 
6.1 Immunomodulation of macrophages with lectin mimetics and glycopolymers 
quantifying cytokine release and cell surface marker changes of 
macrophages 
Glycomic analysis seeks to understand glycans and glycoconjugates and how they react 
and alter the environment around them. More specifically, sialylated glycoconjugates take 
part in many biological processes, from intracellular signaling to organ development and 
tumor growth.5 However, a clear understanding of the underlying mechanisms governing 
glycan-protein communication is not well understood, and even less, how they are involved 
in physiological and pathological processes. Our current studies have shown these lectin 
mimetics have more favorable properties compared to natural lectin in terms of toxicity 
and inherent immunogenicity and will provide an important tool for future glycomics, 
biosensor and immunomodulation research and applications. To understand the underlying 
molecular mechanism of cell modulation and reveal new functions of boronic acid derived 
lectin mimetics, it would be valuable to determine the exact changes in cytokine expression 
as well as cell surface marker changes. 
ELISA based assays are the primary technique for characterizing cytokine expression 
based on easy quantification upon activation. More importantly, the high sensitivity of 
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these types of assays require small amounts of cells, compounds, and reagents. This 
approach generates “high quality” information on compound effects that will be vital in 
designing and discovering immune cell-targeting and modulating glycoligands for 
immunotherapy applications. This study only investigated four cytokines as a model, and 
the investigation of more cytokines will undoubtedly give a deeper understanding of 
cellular mechanisms. However, traditional methods lack the ability for high throughput 
analysis and reagent amounts could be reduced further, eliminating even more excessive 
and costly materials.  
In addition, cell surface marker changes are typically identified using fluorescent 
antibody techniques and suffer from the same drawbacks as ELISA based assays. In this 
study, only four cell surface markers were measured as a model to demonstrate the 
applicability of glycopolymers as cellular modulators. Many more cell surface markers 
could be studied further elucidating cellular communication and signaling mechanisms. As 
carbohydrate roles in cellular communication come to the forefront of biological research, 
the need for an automated, high throughput, 3-D analysis technique becomes increasingly 
necessary and will offer the best glimpse of protein-carbohydrate interactions and the roles 
they play in both therapeutic and diagnostic applications. 
6.2 Investigation of additional macromolecular structures 
In this study, macromolecules were used as a basis for glycan recognition based on an 
increase in multivalency and therefore and increase in affinity. Multiple types of 
multivalent macromolecular structures have been studied including nucleotides, proteins, 
dendrimers, and linear polymers and have had varying results based on their individual 
architecture.6,7 In addition, to the macromolecular “skeleton” structure, the change in 
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number of boronic acids, their orientation, and even boronic acid substituents has major 
implications in the unique abilities of each synthesized molecule. To compensate for 
natural lectins’ limited numbers and immunogenicity, a larger number of synthesized lectin 
mimetics with varying capabilities can increase glycan recognition and cellular 
immunomodulation as well as mitigate drawbacks. Two primary methods exist for this type 
of advancement: combinatorial and specific molecular design. It is my belief that the best 
approach given the current situation is to develop a combinatorial library of additional 
macromolecule structures based on linear polymers and branched dendrimers. The 
techniques for derivatization are already standard lab practice, yet the number of potential 
derivatives means they have not all been studied for glycan recognition and/or cellular 
modulation. As the need for progression in glycomics research becomes more widespread, 
lectin- and glyco- mimetics will inevitably become increasingly more valuable. 
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